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Zusammenfassung  I
Zusammenfassung 
Das körpereigene Immunsystem ist nur teilweise in der Lage, Krebszellen zu erkennen 
und zu vernichten. Krebspatienten besitzen zwar Tumor-spezifische T-Zellen, jedoch 
wird deren Aktivität durch mehrere Mechanismen gestört. Zum Beispiel werden 
zytotoxische T-Zellen durch regulatorische T-Zellen (Treg Zellen) inhibiert. Deshalb ist 
die Aktivierung und Unterstützung von Tumor-spezifischen zytotoxischen T-Zellen eine 
wichtige Aufgabe in der Immuntherapie. Eine vielversprechende Zielstruktur dafür ist 
der „Glucocorticoid-Induced Tumor Necrosis Factor-related Receptor“ (GITR), da 
dieser sowohl auf CD4+ und CD8+ Effektor T-Zellen als auch auf CD4+25+ Treg Zellen 
vorkommt. Die Aktivierung des murinen GITR durch den natürlichen Liganden 
(mGITRL) oder einen agonistischen Antikörper erhöht die Aktivität von Effektor T-
Zellen, hemmt die Suppression durch regulatorische T-Zellen und verzögert das 
Tumorwachstum in diversen Mausmodellen. Die systemische Verabreichung 
kostimulierender Therapeutika führt jedoch häufig zu globaler Aktivierung von 
zytotoxischen T-Zellen und kann somit Autoimmunantworten hervorrufen. Zur 
spezifischen Manipulation von T-Zellen in der unmittelbaren Tumorumgebung haben 
wir ein neuartiges bispezifisches Fusionsprotein entwickelt, das aus dem murinen 
GITR Liganden und einem einkettigen Antikörper mit Spezifität für das „Fibroblast 
Activation Protein“ (FAP) besteht. Eine Tumor-spezifische Anreicherung des 
Fusionsproteins soll durch Bindung an FAP erreicht werden, da dieses spezifisch auf 
aktivierten Fibroblasten im Stroma von epithelialen Tumoren und auf Sarkomzellen 
exprimiert wird.  
Das im Rahmen dieser Doktorarbeit produzierte antiFAP-mGITRL Fusionsprotein 
bildete Dimere und wies eine Affinität von 1.2 μM zu murinem GITR und von 4.5 nM zu 
murinem FAP auf. Durch die Kultivierung von CD8+ und CD4+ T-Zellen mit dem 
Fusionsprotein konnte die T-Zell Proliferation sowie die Produktion von IFN-γ und IL-2 
gesteigert werden. Eine Verstärkung dieses kostimulatorischen Effekts wurde durch die 
Präsentation von antiFAP-mGITRL durch FAP+ Zellen erreicht. Dabei führt 
membranständiges antiFAP-mGITRL vermutlich zur Vernetzung von mehreren GITR-
Molekülen auf der T-Zell Oberfläche, verstärkt dort die Signaltransduktion und resultiert 
in gesteigerter Kostimulation. In vitro Studien zeigten, dass Treg Zellen die Proliferation 
und Funktion von CD8+ T-Zellen hemmen. Durch die Zugabe unseres antiFAP-
mGITRL Fusionsproteins zu einer Kokultur von CD8+ und Treg Zellen konnte die 
Proliferation sowie die IFN-γ-Produktion von CD8+ T-Zellen wiederhergestellt werden. 
Zusammenfassung  II
Des Weiteren war membranständiges antiFAP-mGITRL 100 Mal effektiver als 
ungebundenes Fusionsprotein. Zur Übertragung der in vitro Ergebnisse in ein 
syngenes präklinisches Modell wurden tumortragende Mäuse mit antiFAP-mGITRL 
behandelt. Das Wachstum eines subkutanen Kolonkarzinoms konnte durch 
immuntherapeutische Behandlung mit antiFAP-mGITRL nicht verlangsamt werden, da 
die Stromabildung zu gering war. Die antiFAP-mGITRL Therapie eines FAP+ 
Osteosarkoms führte hingegen zu gesteigertem Überleben. 
Der kostimulatorische Effekt von antiFAP-mGITRL auf T-Zellen sowie die FAP-
spezifische Präsentation des Fusionsproteins bilden die Grundlagen einer spezifischen 
Tumortherapie. Die erwartete Anreicherung von mGITRL im Tumorgewebe soll die 
zytotoxischen T-Zellen lokal unterstützen und das Risiko einer Autoimmunantwort 
minimieren. Somit stellt die Behandlung mit antiFAP-mGITRL einen 
vielversprechenden Ansatz in der Antikörper-basierten Immuntherapie von Tumoren 
dar.  
Abstract  III
Abstract  
Cancer patients possess tumor-reactive T cells but their function is hampered by many 
mechanisms. One of these mechanisms involves naturally occurring regulatory T cells 
(Treg cells) that inhibit effector T cells. Activation or support of the tumor-reactive T 
cells is therefore a major objective in cancer immunotherapy. Stimulation of 
glucocorticoid-induced tumor necrosis factor-related receptor (GITR) represents a 
promising approach since this receptor is expressed on both CD4+ and CD8+ effector T 
cells as well as on CD4+25+ Treg cells. Triggering of murine GITR with its natural ligand 
(GITRL) or anti-GITR agonistic antibodies enhances T cell responses, inhibits Treg-
mediated suppression and thereby induces tumor immunity in a variety of murine tumor 
models. However, systemic administration of costimulatory agents can lead to global T 
cell activation and autoimmunity. Therefore, we propose to specifically manipulate the 
T cell compartment in the tumor microenvironment by using a bispecific fusion protein 
combining mGITRL and a single chain antibody which targets fibroblast activation 
protein (FAP). Accumulation of antiFAP-mGITRL in the tumor microenvironment can be 
mediated through binding to FAP, which is specifically expressed on sarcomas and on 
cancer-associated fibroblasts (CAFs) found in the stroma of epithelial cancers.  
The antiFAP-mGITRL fusion protein generated in this study formed dimers and bound 
to murine GITR with an affinity of 1.2 μM and to murine FAP with an affinity of 4.5 nM. 
In vitro cell assays with murine splenocytes showed that our antiFAP-mGITRL fusion 
protein can stimulate CD8+ and CD4+ effector T cells as shown by their increased 
proliferation and production of IFN-γ and IL-2. This costimulatory effect was enhanced 
when the fusion protein was presented by a FAP-positive cell line mimicking FAP+ 
CAFs or FAP+ tumors. Presumably, the membrane-bound antiFAP-mGITRL allows 
crosslinking of multiple GITR molecules on the T cells, thus leading to increased 
signaling and enhanced costimulation. In vitro, Treg cells inhibit the expansion and 
function of CD8+ T cells. Addition of our antiFAP-mGITRL to the Treg:CD8+ T cell 
coculture could restore proliferation and IFN-γ production of CD8+ T cells. Furthermore, 
cell membrane-bound antiFAP-mGITRL was 100-fold more effective in overcoming 
Treg-mediated suppression compared to unbound fusion protein. To translate the in 
vitro results in a preclinical model, we established syngeneic murine cancer models to 
either target the tumor stroma or the tumor cells directly. Immunotherapeutic antiFAP-
mGITRL treatment of a colon carcinoma provoked no delay in tumor growth due to 
Abstract  IV
weak stroma formation. However, therapy of a FAP+ osteosarcoma led to enhanced 
survival of mice treated with antiFAP-mGITRL. 
The antibody-directed delivery of GITRL opens a new path to positively act on the local 
T cell environment in the tumor. Targeted delivery and thereby enhanced 
immunomodulatory effects of antiFAP-mGITRL represent a promising approach in 
antibody-based tumor immunotherapy. 
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1 Introduction  1
1 Introduction 
1.1 Immunotherapy of tumors 
With cancer still being the second most common cause of death in the western world, 
after cardiovascular diseases, there is a great need for novel treatment options. Most 
conventional therapy protocols for solid cancers involve surgery combined with 
radiation or chemotherapy. Success of these treatment strategies is limited by 
accessibility of the tumor and side effects of the therapy. A major requirement for 
effective and well-tolerated cancer therapies is the selective delivery of therapeutics to 
the site of disease. The advances in molecular biology, especially recombinant 
antibody technology (Hoogenboom, 2005), along with a better understanding of the 
mechanisms of our immune system provide a strong basis for the development of 
cancer immunotherapy.  
While early reports already postulated that our immune system recognizes modified 
cells and fights the formation and development of cancer (Burnet, 1970; Ehrlich, 1900; 
Thomas, 1959), this theory is now accepted as the concept of immune surveillance 
(Dunn et al., 2004). It can be described by the three Es of cancer immunoediting – 
elimination, equilibrium and escape: The immune system protects the host from 
neoplastic disease by recognizing and eliminating these modified cells. However, 
elimination of the tumor cells is not complete and after a transient equilibrium phase, 
some transformed cells escape the control of the immune system. Various escape 
strategies like loss of antigen expression, downregulation of MHC molecules, 
development of resistance to IFN-γ, generation of an immunosuppressive 
microenvironment through secretion of cytokines such as TGF-β and IL-10 or 
mechanisms involving suppressive T cells (regulatory T cells) have been reported to 
lead to the development of cancer (Smyth et al., 2001). Tumor cell variants with low 
immunogenicity are selected in the equilibrium phase and eventually grow. Indeed, 
Robert Schreiber and colleagues showed in 2001 that mice lacking T, B and NKT cells 
develop chemically-induced carcinoma faster and at a higher rate than wild type mice 
(Shankaran et al., 2001), thereby validating the concept of cancer immunosurveillance.  
Greater understanding of the 3 phases of immunoediting, especially the escape phase, 
has led to the development of new paths in cancer treatment. The aim is to restore the 
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immune response against the tumor, e.g. through prophylactic and therapeutic 
vaccination, adoptive T cell therapy or antibody-based tumor therapy. A dozen of 
antibodies are already approved for the treatment of a wide variety of cancers and 
several dozens of antibodies are in phase I to III clinical trials. Furthermore, 
combination therapy such as monoclonal antibodies (mAb) with high-dose IL-2 or with 
chemotherapy is common. Most mAb approved by the regulatory authorities to date 
involve naked Immunoglobulin G (IgG) like Herceptin against metastatic breast cancer, 
Rituxan for the treatment of non-Hodgkin’s lymphoma or Erbitux for metastatic 
colorectal cancer (Dean-Colomb and Esteva, 2008; Hauptrock and Hess, 2008; Rivera 
et al., 2008). Additionally, the radiolabeled IgGs Zevalin (Borghaei and Schilder, 2004; 
Marcus, 2005) and Bexxar (Vose, 2004; Wahl, 2005) are used for the treatment of non-
Hodgkin B-cell lymphoma and the antibody drug conjugate Mylotarg (Bross et al., 
2001; Linenberger, 2005) is approved for the treatment of acute myeloid leukemia. 
1.2 Targets for immunotherapy 
Tumor targeting strategies rely on the identification of good quality targets. For highly 
specific therapy results, restricted expression patterns of these targets are required. 
Optimal targets should be abundant at the tumor site for accumulation of the 
therapeutic agent, not be expressed on vital organs to avoid side-effects, not be 
secreted since the mAb would bind the excess antigen instead of reaching the tumor 
and, finally, they should be well accessible for circulating agents. The target structures 
are called tumor-associated antigens (TAAs) and may be unique to an individual tumor 
or common to a tumor type. Furthermore, some tumor antigens are normal cellular 
antigens that are highly overexpressed on tumors. TAAs can be classified by their 
localization either on tumor cells directly or on structures in the tumor 
microenvironment.  
Targeting TAAs on the surface of malignant cells has been proven to be effective and 
specific in the treatment of certain cancers. The antigen is usually expressed at very 
high levels on the cancer cells. Nevertheless, a major drawback is the development of 
resistance to treatment, e.g. through outgrowth of antigen loss mutants (cf. section 
1.1). An example for a TAA expressed on the tumor cell surface is human epidermal 
growth factor receptor 2 (HER2) which is targeted by Trastuzumab that acts through 
downmodulation of HER2-mediated signaling and increased tumor cell apoptosis 
(Dean-Colomb and Esteva, 2008; Nahta and Esteva, 2006). Many tumor markers, 
however, are intracellular proteins and thus not accessible to recognition by antibodies 
1 Introduction  3
or immune cells. Peptides derived from these intracellular TAAs are presented on the 
surface of the tumor cell in the context of the MHC I system. These peptide-MHC 
complexes are specifically recognized by T lymphocytes through their T cell receptor 
(TCR). In the presence of costimulatory signals, the activated T cells can then exert 
their antitumor activity. 
An alternative to targets on tumor cells, are TAAs in the tumor microenvironment 
(TME). These targets have great advantages since TME components are genetically 
more stable than tumor cells and the TME shares many features among different tumor 
types. Thus, targeting of these common structures has the potential to cure a greater 
variety of patients. TME targets can be divided in targets on immune cells and tumor 
stroma targets.  
Tumor-infiltrating immune cells can be manipulated through targeting of structures on 
antigen presenting cells (APC) that present tumor antigens via their MHC, effector T 
(Teff) cells with cytotoxic activity and regulatory T cells with suppressive activity. For 
example, the function of dendritic cells (DCs) can be modulated by vaccination with 
peptide and stimulating agent (adjuvant, antibody). Thereby, naïve antigen presenting 
DCs are activated and matured so that they can prime T cells in secondary lymphoid 
organs. Furthermore, the supply of costimulatory and coinhibitory signals to T cell 
coreceptors is crucial for the generation and maintenance of immune responses. A 
more detailed insight into the role of T cells in cancer and options for therapeutic 
interventions is given in sections 1.4 and 1.6. 
The stromal compartment commonly makes 20% to 50% of the mass of epithelial 
cancers (Welt et al., 1994). It is constituted of blood and lymphoid vessels, the 
extracellular matrix, mesenchymal cells, fibroblasts and inflammatory cells and 
molecules. Angiogenesis markers are popular tumor therapy targets. For example, the 
antibody L19 targets the tumor vasculature by recognizing the extra-domain B of 
fibronectin which becomes inserted into fibronectin under tissue-remodeling conditions, 
such as cancer (Zardi et al., 1987). As another approach, structures on cancer-
associated fibroblasts (CAF) found in the TME can be targeted for tumor therapy. CAFs 
are phenotypically and functionally distinct from the fibroblasts present in tissues and 
have been shown to promote tumor growth in several mouse experiments (Liao et al., 
2009; Orimo et al., 2005). Therefore, targeting and inhibiting CAFs has great potential 
in tumor therapy. An interesting target structure on CAFs is fibroblast activation protein 
(FAP) which can be targeted by small molecules (Adams et al., 2004) or antibodies 
(Scott et al., 2003) as described in more detail in the next section.  
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1.3 Fibroblast activation protein 
Fibroblast activation protein (FAP) was first described as the target of mAb F19 which 
had been generated by immunizing a mouse with cultivated lung fibroblasts (Rettig et 
al., 1986). FAP is a 95 kDa type II transmembrane protein with serine protease and 
collagenase activity (Scanlan et al., 1994). Its capacity to degrade type I collagen (Park 
et al., 1999) explains the implication of FAP in extracellular matrix remodeling. 
On one hand, FAP is expressed on tumor cells directly such as sarcomas (Dolznig et 
al., 2005; Scanlan et al., 1994). On the other hand, FAP is expressed on cancer-
associated fibroblasts found in the stroma of about 90% of all human epithelial cancers 
such as breast, lung or colorectal carcinomas (Garin-Chesa et al., 1990; Rettig et al., 
1993; Scanlan et al., 1994) and in the stroma of some melanoma (Huber et al., 2003). 
This dual expression pattern of FAP allows targeting of a wide variety of cancers. High 
expression of FAP is restricted to tumors, but some levels of FAP have also been 
detected in conditions of active stroma remodeling such as wound healing (Garin-
Chesa et al., 1990), rheumathoid arthritis (Bauer et al., 2006) or cirrhotic liver (Levy et 
al., 1999).  
High expression of FAP in the tumor microenvironment correlates with poor prognosis 
(Cohen et al., 2008; Henry et al., 2007) and several animal experiments suggest that 
FAP promotes tumor growth and metastasis. FAP knockout mice show no overt 
pathology (Niedermeyer et al., 2000) and have reduced tumorigenesis (Santos et al., 
2009). Overexpression of FAP enhances tumor growth (Cheng et al., 2005; Huang et 
al., 2004) whereas treatment with antibodies (Cheng et al., 2002) or small molecules 
(Adams et al., 2004) inhibiting the proteolytic activity of FAP attenuates tumor growth in 
a mouse model. Immunization of mice through administration of a DNA vaccine 
encoding FAP (Loeffler et al., 2006) or the use FAP-transfected DCs (Lee et al., 2005) 
did also suppress primary tumor growth as well as metastasis. Without affecting the 
activity of FAP, long-lasting inhibition of tumor growth and complete regressions could 
be achieved with an anti-FAP-maytansinoid conjugate in mice, thereby confirming the 
potential of FAP as a localization target (Ostermann et al., 2008). Successful tumor 
staining (Brocks et al., 2001; Cheng et al., 2002) with FAP-specific monoclonal 
antibodies has been reported in murine xenografts and human tumors. Although in vivo 
imaging of human FAP-positive tumors with the humanized 131I-labeled mAb F19 was 
successful (Scott et al., 2003), no antitumor activity in metastatic colorectal cancer 
could be achieved (Hofheinz et al., 2003; Scott et al., 2003). To date, there are no anti-
human FAP antibodies that also inhibit FAP activity.  
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1.4 T lymphocytes in the antitumor response 
Cytotoxic T cells have been shown to be a major player in the antitumor response. 
Activation of such tumor-specific T cells is the result of a complex interplay between 
different components of our immune system (Dunn et al., 2004; Smyth et al., 2001). 
One of the first steps in the induction of an immune response is the presentation of 
epitopes from TAAs in the context of MHC class I and class II complexes. For this, 
peptides that are shed by tumors or peptides deriving from dying tumor cells are 
captured by naïve APCs, processed and small fragments are presented via the MHC 
complex. If tumors deliver danger signals, such as heat shock proteins or IFN-α, the 
APCs are activated and, in turn, upregulate their costimulatory molecules. The resulting 
mature APCs migrate to the draining lymph nodes where they stimulate T cells. APCs 
prime CD4+ T cells via their peptide-MHC II complex and CD8+ T cells via their peptide-
MHC I complex and deliver costimulatory signals to both T cell subsets via, e.g. , the 
B7-CD28 interaction. By these means, T cells are activated in an antigen-specific 
manner. The TAA-specific T cells differentiate into cytotoxic CD8+ T lymphocytes 
(CTLs) and CD4+ T helper 1 cells (Th1) that migrate from the lymph node to the tumor. 
Local APCs further stimulate the T cells directly at the tumor site. The role of Th1 cells 
is to support the viability and function of CTLs through secretion of IL-2. CTLs kill tumor 
cells via direct mechanisms through death receptor triggering (Fas-FasL interaction) or 
release of perforin and granzyme B and through indirect mechanisms via TNF-α. 
Furthermore, CTLs release pro-inflammatory cytokines such as IFN-γ which inhibits 
cell proliferation, inhibits angiogenesis, promotes apoptosis, stimulates the adaptive 
immune system and enhances antigen-processing and presentation, thereby 
participating in cancer elimination. 
Although our immune system provides the tools for an antitumor response, tumors do 
develop. The principal reason is that the majority of tumor-associated antigens are self-
antigens. Indeed, members of the cancer-germ line group (such as MAGE-A4 or NY-
ESO-1) or melanoma differentiation antigens (such as MART-1 and tyrosinase) are 
presented by medullary thymic epithelial cells (Gotter et al., 2004). Therefore, the 
immune response against these antigens is impaired by either central tolerance where 
high and intermediate affinity self-reactive T cells are deleted by negative selection in 
the thymus or by peripheral tolerance through suppressive activity by regulatory T cells. 
Independently of the type of the tumor antigen, numerous other mechanisms alter the T 
cell activity in patients. Tolerance of tumors can be induced by secretion of anti-
inflammatory cytokines such as TGF-β or IL-10 by the tumor, thereby directly impeding 
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CTL and Th1 function. Furthermore, tumors don’t always deliver danger signals to the 
environment, thereby failing to activate APCs which in turn induces T cell tolerance 
instead of T cell activation. Finally, anti-inflammatory cytokines secreted by NKT cells 
or type 2 macrophages can inhibit both APCs and T cells.  
1.5 Regulatory T cells 
Immunologic self-tolerance is maintained by regulatory T cells exhibiting suppressive 
activity. Characterization of these cells has shown that many types of regulatory T cells 
coexist. Naturally-occurring regulatory T cells originate in the thymus whereas adaptive 
regulatory T cells such as IL-10/TGF-β secreting Tr1 regulatory T cells or TGF-β/IL-
4/IL-10 secreting Th3 helper T cells are induced in the periphery by conversion of 
CD4+25- T cells (Bach, 2003; Roncarolo and Levings, 2000; Weiner, 2001). 
Naturally-occurring CD4+25+ regulatory T cells (Treg cells) constitute 5 to 10% of the 
peripheral CD4+ T cell subset in the blood. Constitutive high expression of the IL-2 
receptor α chain (CD25) has been widely used as a Treg cell marker despite being also 
present on activated effector T lymphocytes. Treg cells also constitutively express 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) (Read et al., 2000; 
Takahashi et al., 2000) and glucocorticoid-induced tumor necrosis factor related 
receptor (GITR) (McHugh et al., 2002). In mice, intracellular expression of the 
transcription factor forkhead box P3 (Foxp3) is the most specific marker for this cell 
population (Fontenot et al., 2003; Hori et al., 2003). Foxp3-/- mice completely lack 
CD4+25+ T cells and exhibit lethal lymphoproliferative autoimmune disease but 
adoptive transfer of Treg cells rescues the mice from the lethal phenotype (Fontenot et 
al., 2003; Khattri et al., 2003). The regulatory phenotype is maintained by the 
transcriptional complexes involving Foxp3, NFAT (Nuclear factor of activated T cells), 
NF-κB and AML1/Runx1 that repress IL-2 and IFN-γ production and upregulate 
expression of CD25 and CTLA-4 on Treg cells (Bettelli et al., 2005; Sakaguchi et al., 
2008; Wu et al., 2006).  
Treg cells do not proliferate upon TCR stimulation, however, IL-2 or costimulatory 
signals can break their anergic state. Treg cells require antigen-specific or polyclonal 
TCR stimulation to exert their suppressive function. Once activated, they suppress in 
an antigen-non-specific manner, meaning that they do not only suppress the 
proliferation and expansion of T cells with the same antigen specificity but also of T 
cells recognizing other targets. Besides acting on T cells, Treg cells also inhibit the 
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function of other immune cells. The mechanisms for Treg-mediated immune 
suppression are not fully elucidated yet and have been reviewed extensively. Effector 
mechanisms can be divided by those targeting T cells and those inhibiting APCs. Treg 
cells secrete inhibitory cytokines such as IL-10, TGF-β and IL-35 and thereby inhibit 
effector T cell function. Another proposed mechanism is IL-2 deprivation of Teff cells, 
leading to Bim-mediated apoptosis of Teff cells. Furthermore, Teff cells may directly be 
killed by Treg cells in a granzyme- or perforin-dependent manner. Cell-surface 
molecules such as Galectin-1 or other yet unknown molecules can induce cell cycle 
arrest in Teff cells. By inhibiting APCs, Treg cells indirectly prevent the activation of 
Teff cells. CTLA-4-mediated downregulation of CD80 and CD86 on APCs decreases 
their costimulatory effect and interaction of LAG-3 with MHC II molecules suppresses 
DC maturation. Moreover, Treg cells can form stable complexes with APCs, thereby 
outcompeting the binding to naïve T cells and preventing their priming (Bettini and 
Vignali, 2009; Rudensky and Campbell, 2006; Sakaguchi et al., 2009; Shevach, 2009). 
Through these mechanisms, Treg cells are able to sustain peripheral tolerance but they 
also hamper the immune responses against cancer. 
1.6 Costimulation of T cells for tumor therapy 
Strong infiltration of CD4+25+Foxp3+ T cells in the tumor correlates with poor prognosis 
in hepatocellular carcinoma (Gao et al., 2007) and ovarian cancer patients (Curiel et 
al., 2004). In contrast, high CD8+/Treg ratios were reported to be associated with 
improved survival (Gao et al., 2007; Sato et al., 2005). A promising strategy in tumor 
therapy is therefore to act on the local balance of effector T cells and Treg cells 
exclusively in the tumor microenvironment by either supporting the tumor-reactive T 
cells or inhibiting the suppressive T cell population. 
Shimizu et al. have first demonstrated in 1999 that elimination of CD4+CD25+ T cells 
elicits potent tumor-specific immune responses to syngeneic tumors in vivo and 
eradicates them. Ever since then, therapeutic strategies are being developed to inhibit 
Treg cell function, deplete the Treg cell population or prevent their migration to the 
tumor site. Treg cell recruitment to the tumor has been inhibited by blockade of the 
Treg-attracting chemokine CCL5 (C-C chemokine ligand 5), thereby leading to delayed 
tumor growth in a murine pancreatic tumor model (Tan et al., 2009). Alternatively, 
CD25+ T cells can be depleted in mice by administration of anti-CD25 mAb (clone 
PC61) but treatment prior to tumor inoculation or up to day 1 afterwards is required to 
achieve tumor rejection (Onizuka et al., 1999; Shimizu et al., 1999). Since selective 
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depletion of Treg cells has been proven to be difficult due to unavailability of specific 
markers, functional inhibition of Treg cells has been investigated. For example, 
activation of Toll-like receptor 8 (TLR8) in humans (Peng et al., 2005) or stimulation of 
OX40 on Treg cells in mouse models (Colombo and Piconese, 2007) block Treg-
mediated suppression. Besides inhibiting Treg cells, such treatments often also act 
directly on effector T cells. Indeed, Teff cells are rendered resistant to suppression by 
Treg cells through the action of costimulatory molecules. Therefore, modulation of 
effector T cells has been exploited in many therapy models. Therapeutic interventions 
in cancer models include the supply of mAb or ligands which costimulate T cells (anti-
CD28, anti-CD137, anti-OX40, anti-GITR, anti-CD40) or the removal/blockade of 
coinhibitory signals (anti-CTLA-4, anti-B7-H1, anti-PD-1) as reviewed (Melero et al., 
2007; Peggs et al., 2009). Costimulation of CD28 on Teff cells with a CD80-Fc fusion 
protein delayed tumor growth in a syngeneic mouse model (Liu et al., 2005). 
Furthermore, blocking CTLA-4 signaling enhanced T cell responses and led to tumor 
rejection in several mouse models (Leach et al., 1996; Sutmuller et al., 2001; van Elsas 
et al., 1999). In clinical trials, CTLA-4 blocking antibodies Ipilimumab and 
Tremelimumab induced durable clinical responses in patients with metastatic 
melanoma (O'Day et al., 2007; Phan et al., 2003; Ribas et al., 2007). Combination of 
Ipilimumab with IL-2 led to 22% of partial and complete response in a phase II clinical 
trial (Maker et al., 2005).  
Although tremendous improvements have been made in the field of immunotherapy in 
the last decade, systemic immune intervention can have severe side effects. A 
significant innovation has been the introduction of bispecific fusion proteins that 
specifically deliver the active molecule to the tumor site.  
1.7 Combination of antibodies and effector molecules for 
immunotherapy 
Full-length IgGs mediate their antitumor effect by blocking the receptor-ligand 
interaction (Cetuximab, Bevacizumab), altering cell signaling (Trastuzumab), activating 
antibody-dependent cellular cytotoxicity (ADCC) or mediating complement-dependent 
cytotoxicity (CDC) through the Fc domain (Rituximab). However, only few antibodies 
are approved and the antitumoral effects are not sufficient so that combination with 
other treatment options, such as chemotherapy, is required. By combining an antibody 
fragment with a bioactive molecule, it is possible to chose virtually any effector function 
and deliver therapeutic moieties specifically to the site of disease. Most importantly, 
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targeted delivery of the often toxic agents to the tumor permits to spare healthy tissue 
resulting in minimal side effects.  
Immunoconjugates combining radionuclides with antibody fragments are powerful tools 
for both diagnostic (Dancey et al., 2009; Milenic et al., 2004) and therapeutic (Borghaei 
and Schilder, 2004; Wahl, 2005) applications. Ibritumomab tiuxetan (Borghaei and 
Schilder, 2004; Marcus, 2005) and Tositumomab (Vose, 2004; Wahl, 2005) are two 
CD20-specific murine mAbs conjugated with beta-emitting radionuclides (90Y and 131I, 
respectively) approved for the treatment of non-Hodgkin B-cell lymphoma. However, 
radioimmunoconjugates bear certain complexities linked to the type and energy of 
emission, radiolabeling process of the mAb and half-life of the construct.  
The only approved antibody-drug conjugate is Mylotarg (Bross et al., 2001; 
Linenberger, 2005; Sievers and Linenberger, 2001) which combines a humanized 
CD33-specific mAb with the drug calicheamicin. This complex induces cytotoxic 
effects, probably due to DNA double strand breaks after internalization of the complex, 
leading to overall response rates of ~30% in acute myeloid leukemia (Sievers and 
Linenberger, 2001).  
Besides full-length IgGs, other antibody formats have been fused with therapeutic 
agents. scFv antibody fragments are the format of choice for the delivery of the active 
molecule to the site of disease. Since scFv immunoconjugates are encoded in a single 
molecule, production of the fusion protein is easier than an IgG immunoconjugate. 
Furthermore, the small size of scFv immunoconjugates leads to better tumor uptake 
than higher molecular weight molecules. An example of such an immunoconjugate is 
the anti-CD22 scFv fused to truncated Pseudomonas exotoxin A (Kreitman et al., 
2009). Although 61% complete remission in hairy cell leukemia patients could be 
achieved with this antibody-toxin conjugate, severe side effects such as vascular leak 
syndrome were detected.  
Since some drugs are very harmful in vivo and selective targeting might not be 
sufficient to avoid systemic toxicity, the method of antibody-directed enzyme prodrug 
therapy (ADEPT) was developed. First, an enzyme conjugated to an antibody fragment 
is administrated and accumulates in the tumor. In a second step, a non-toxic prodrug is 
given and then specifically activated by the enzyme at the tumor site. Although some 
clinical response could be obtained with this system, the conjugated enzymes are 
highly immunogenic if of bacterial or murine origin and make repeated treatment 
impossible (Bagshawe et al., 2004; Cortez-Retamozo et al., 2004; Napier et al., 2000; 
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Siemers et al., 1997). To approach this problem, human enzymes have to be tested in 
a clinical setting.  
Use of proinflammatory signals is a promising approach to induce tumor immunity 
(Fishman and Seigne, 2002). However, untargeted cytokines are highly toxic and can 
only be applied by isolated limb perfusion (Eggermont et al., 1996). Combination of 
these cytokines with a targeting component can avoid systemic effects. 
Proinflammatory cytokines IL-2, IL-12 and TNF-α fused to the L19 scFv recognizing the 
extradomain B of fibronectin have shown therapeutic effects in preclinical tumor models 
(Borsi et al., 2003; Carnemolla et al., 2002; Halin et al., 2003) and are currently in 
clinical development (Rybak et al., 2007). Further fusion proteins investigated in 
preclinical models include antiCD30-IL-2 (Hirsch et al., 2009), antiErbB2-B7.2 
(Gerstmayer et al., 1997) and antiFAP-4-1BBL (Muller et al., 2008). 
1.8 Glucocorticoid-induced tumor necrosis factor-related 
receptor and its ligand 
In recent years, great attention has been dedicated to the murine glucocorticoid-
induced tumor necrosis factor-related receptor (mGITR). GITR is a 228 amino acids 
type I transmembrane protein first cloned in 1997 from a murine T cell hybridoma 
stimulated with the glucocorticoid dexamethasone (Nocentini et al., 1997). Murine 
GITR is expressed at low levels on naive T cells and is upregulated through TCR 
stimulation on both CD4+ and CD8+ responder cells (Kanamaru et al., 2004; McHugh et 
al., 2002; Nocentini et al., 1997; Ronchetti et al., 2004). In contrast, GITR is 
constitutively expressed at high levels on CD4+25+ regulatory T cells and further 
upregulated upon stimulation (Kanamaru et al., 2004; McHugh et al., 2002; Nocentini et 
al., 1997). The ligand for GITR (GITRL) is a 173 aa type II transmembrane protein and 
is expressed on macrophages, immature and mature DCs and B cells (Tone et al., 
2003).  
GITR has been classified as member number 18 of the tumor necrosis factor receptor 
superfamily and is part of the costimulatory setting of a T cell. GITR triggering leads to 
NF-ĸB and MAPK (mitogen-activated protein kinase) activation thus provoking survival 
and proliferation of T cells (Esparza and Arch, 2005; Ji et al., 2004; Kim et al., 2003; 
Ronchetti et al., 2004). Indeed, activation of murine splenocytes with soluble (Tone et 
al., 2003) or membrane-bound GITRL (Cho et al., 2009; Kanamaru et al., 2004; 
Stephens et al., 2004) or with agonistic anti-GITR antibodies (Nishioka et al., 2008; 
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Ronchetti et al., 2004; Shimizu et al., 2002), leads to proliferation and to cytokine 
release by CD4+ and CD8+ effector T cells. Furthermore, in vitro addition of GITRL 
reduces Treg-mediated suppression (Hu et al., 2008; McHugh et al., 2002; Shimizu et 
al., 2002; Stephens et al., 2004; Valzasina et al., 2005). It has long been a matter of 
debate if ligation of GITR on regulatory T cells or on effector T cells is responsible for 
abrogation of Treg-mediated suppression. Preincubation of Treg cells with anti-GITR 
antibody, before adding the effector T cells, abrogates the suppressive effect (McHugh 
et al., 2002; Valzasina et al., 2005) thus suggesting a direct effect of GITR triggering on 
CD4+25+ Treg cells. However, use of GITR-/- mice has shown that activation of GITR on 
CD4+25- cells and not on Treg cells is responsible for inhibiting suppression (Stephens 
et al., 2004). It has further been reported that CD8+ and CD4+ T cells are being 
rendered resistant to suppression through GITR stimulation by GITRL or agonistic anti-
GITR mAb DTA-1 in tumor models (Nishikawa et al., 2008; Zhou et al., 2007). Little 
attention has been dedicated to reverse signaling through GITRL so far. A role in 
promoting immunosuppression has been proposed, thereby, preventing excessive 
costimulation through GITR activation, but no conclusive model of GITRL triggering has 
been established yet (Agostini et al., 2005; Grohmann et al., 2007; Shin et al., 2004; 
Shin et al., 2002).  
The T cell costimulatory properties of GITR activation have been exploited for tumor 
immunotherapy in mouse models. Tumor growth could be successfully inhibited by 
activation of GITR with various formats of the natural ligand, e.g. through administration 
of Fc-mGITRL construct (Hu et al., 2008), mGITRL-transfected cells (Calmels et al., 
2005; Cho et al., 2009; Piao et al., 2009) or a DNA vaccine encoding mGITRL and the 
tumor antigen mERK (mutated extracellular signal-regulated kinase 2) (Nishikawa et 
al., 2008). Stimulation of GITR with agonistic antibodies alone (clones DTA-1, G3c) (Ko 
et al., 2005; Nishioka et al., 2008; Ramirez-Montagut et al., 2006), in combination with 
vaccination against a melanoma differentiation antigen (Cohen et al., 2006) or adoptive 
transfer of tumor-primed CD4+ T cells (Liu et al., 2009) also enhanced the tumor-
specific T cell response and in some cases led to tumor eradication. Success of the 
anti-GITR treatment was at least in part mediated by enhanced infiltration of CD8+ T 
cells and a decrease of Treg cell numbers in the tumor (Cho et al., 2009; Ko et al., 
2005). While in vivo GITR stimulation has been proven to induce or enhance tumor 
immunity, some autoimmune side effects could be observed. Administration of DTA-1 
to BALB/c mice results in moderate titers of anti-parietal autoantibodies occasionally 
accompanied by mild autoimmune gastritis (Ko et al., 2005; Shimizu et al., 2002). 
Systemic administration leads to more autoantibody detection than local tumor injection 
of DTA-1. Autoimmune response in the form of hypopigmentation could be observed in 
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a study where DNA vaccination in combination with DTA-1 treatment was applied for 
tumor therapy (Cohen et al., 2006).  
1.9 Aim of the thesis 
This study exploits the concept of tumor targeting to locally manipulate the T cell 
compartment. The aim is to activate tumor-specific T cells and thereby elicit an 
effective anti-cancer immune response resulting in regression of the tumor.  
We propose to target the therapeutic agents specifically to the site of disease by using 
a fusion protein combining the costimulatory molecule GITRL with an antibody 
fragment targeting FAP. Using the costimulatory properties of GITRL, we aim at 
expanding and activating CD4+ and CD8+ T cells and diminishing the suppression of 
CD8+ T cells by Treg cells. Furthermore, presentation of antiFAP-mGITRL by a FAP+ 
cell line is expected to enhance this stimulation of T cells and further increase their 
resistance to Treg-mediated suppression. We hypothesize that membrane-bound 
antiFAP-mGITRL allows crosslinking of multiple GITR molecules on the T cells, thus 
leading to increased signaling and enhanced costimulation. The in vitro therapeutic 
efficacy of antiFAP-mGITRL is investigated by treatment of mice carrying a 
subcutaneous stroma-inducing carcinoma or a FAP+ sarcoma. 
AntiFAP-mGITRL immunotherapy not only has the potential to enhance therapeutic 
efficacy of GITRL through crosslinking of receptor molecules but also to reduce a 
harmful autoimmune response. 
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2 Material and Methods 
2.1 Equipment 
Agarose Gel Documentation BioDoc-It Imaging System UVP, Upland, USA 
Autoclave V-100 Systec, Hünenberg, 
Switzerland 
BIAcore T100 GE 
Healthcare/Biacore, 
Uppsala, Sweden 
Blotting apparatus Trans-Blot SD Semi-Dry 
Transfer Cell 
Bio-Rad, Hercules, 
USA 
Cell counter CASY Cell Counter Model TT Roche Innovatis, 
Bielefeld, Germany 
Centrifuges Centrifuge 5804R  
Centrifuge 5810R 
Centrifuge 5415D 
Eppendorf, Hamburg, 
Germany 
Electroporation Gene Pulser II Bio-Rad, Hercules, 
USA 
Flow cytometers FACScan 
FACSCalibur 
FACSCanto II 
BD Biosciences, San 
Jose, USA 
FibraStage cell culture 
system 
FibraStage New Brunswick 
Scientific, Edison, USA
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HPLC HP 1100 Series System Agilent Technologies, 
Basel, Switzerland 
Magnetic-activated cell 
sorting 
MACS Multistand & quadro 
MACS 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
PCR cycler T300 Thermocycler Biometra, Göttingen, 
Germany 
Plate reader Wallac Victor2 1420 Multilabel 
Counter 
PerkinElmer, Waltham, 
USA 
Microscope Polyvar 2 Leica Reichert Jung, 
Heerbrugg, 
Switzerland 
Shaker system Multitron 2 Infors HT, Bottmingen, 
Switzerland 
Spectrometer BioPhotometer Eppendorf, Hamburg, 
Germany 
Spinner flask & magnetic 
stirrer 
500 ml flat bottom hanging 
bar spinner flask & BELL-
ENNIUM 9 position magnetic 
stirrer 
Bellco, Vineland, USA 
Water purification Milli-Q Gradient System Millipore, Bedford, 
USA 
Western blot detection unit ChemiDoc-It Imaging System 
with BioChemi HR Camera 
UVP, Upland, USA 
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2.2 Reagents and kits 
2.2.1 Kits 
BCA Protein Assay Kit, Pierce Biotechnology, Rockford, USA 
BD OptEIA Set Mouse IFN-γ, BD Biosciences, San Diego, USA 
BD OptEIA Set Mouse IL-2, BD Biosciences, San Diego, USA 
In-Fusion Dry-Down PCR Cloning Kit, Clontech Laboratories, Mountain View, USA 
QIAGEN Plasmid Maxi Kit, QIAGEN, Hilden, Germany 
QIAprep Spin Miniprep Kit, QIAGEN, Hilden, Germany 
QIAquick Gel Extraction Kit, QIAGEN, Hilden, Germany 
Rapid DNA Ligation Kit, Roche Diagnostics, Mannheim, Germany 
REDTaq Ready Mix, Sigma-Aldrich, St. Louis, USA 
2.2.2 Antibodies 
2.2.2.1 Primary antibodies 
anti-c-myc (9-E10, Novus Biologicals, Littleton, USA)  
mouse monoclonal Penta-His antibody (QIAGEN, Hilden, Germany) 
antiHis-biotin (Rockland Immunochemicals, Gilbertsville, PA) 
anti-mouse CD4 FITC, anti-mouse CD4 APC, anti-mouse CD8 APC (Miltenyi Biotec, 
Bergisch Gladbach, Germany),  
anti-mouse CD8a FITC, anti-mouse CD8 PerCP (BD Biosciences, San Jose, USA) 
anti-mouse CD25 PE, anti-mouse CD4 APC-Alexa750, anti-mouse CD3 PE-Cy7, anti-
mouse CD3 (clone 145-2C11)  (eBioscience, San Diego, USA) 
mouse CD3/CD28 Dynabeads (Invitrogen, Carlsbad, USA) 
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ESC11 IgG, ESC14 IgG (both recognizing murine and human FAP), vF19 (specific for 
human FAP) (all produced in-house, manuscript in preparation)  
PE-conjugated H-2Ld/AH-1138-147 tetramer (SPSYVYHQF) was kindly provided by P. 
Guillaume and I. Luescher (Ludwig Institute Core Facility, Lausanne, Switzerland) 
2.2.2.2 Secondary antibodies 
polyclonal goat anti-mouse immunoglobulins/HRP (Dako, Glostrup, Denmark) 
anti-human F(ab')2 PE, anti-mouse IgG (H+L) biotin, anti-human (H+L) biotin, 
streptavidin PE, peroxidase-conjugated anti-bovine IgG (H+L) , AffiniPure F(ab’)2 
Fragment goat anti-mouse IgG (Jackson ImmunoResearch, Suffolk, UK) 
human κ IgG (Sigma-Aldrich, St Louis, USA) 
2.3 Buffer 
Chemical reagents listed here were purchased from the following manufacturers: 
Merck (Darmstadt, Germany), Bio-Rad (Hercules, USA), SERV Electrophoresis 
(Heidelberg, Germany), Invitrogen (Carlsbad, USA), Sigma-Aldrich (St. Louis, USA), 
Kantonsapotheke (Zürich, Switzerland), Roth (Karlsruhe, Switzerland), Fluka (Buchs, 
Switzerland), Hänseler (Herisau, Switzerland). 
TAE 2 mM 
0.25 mM 
0.5 mM 
TRIS Ultra 
Acetic acid 
EDTA 
PBS 150 mM 
10 mM 
1.5 mM 
NaCl 
Na2HPO4 
KH2PO4 
0.1% PBST  
0.1% (v/v) 
PBS 
Tween20 
10%, 2% MPBS  
10%, 2% 
PBS 
Milk powder 
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PBS-10% glycerol  
10% (v/v) 
PBS 
Glycerol 
FACS buffer 
 
 
2% (v/v) 
0.03% (w/v) 
20 mM 
PBS 
FBS, heat-inactivated 
Sodium azide 
EDTA 
TE 
 
10 mM 
1 mM 
TRIS Ultra 
EDTA 
Adjust to pH8 
5x SDS loading buffer 0.28 M 
1% (w/v) 
30% (v/v) 
0.0012% (w/v) 
5.5% (v/v) 
TRIS Ultra 
SDS 
Glycerol 
Bromophenol blue 
β-mercaptoethanol 
1.5 M TRIS/SDS pH 8.8 1.5 M 
0.4% (w/v) 
TRIS Ultra 
SDS 
Adjust to pH8.8 
0.5 M TRIS/SDS pH 6.8 0.5 M 
0.4% (w/v) 
TRIS Ultra 
SDS 
Adjust to pH6.8 
12% (v/v) running gel 35% (v/v) 
40% (v/v) 
25% (v/v) 
0.01% (v/v) 
0.0005% (v/v) 
dH2O 
Acrylamide (30%) 
1.5 M TRIS/SDS pH 8.8 
APS 
Temed 
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5% (v/v) stacking gel 61% (v/v) 
13% (v/v) 
25% (v/v) 
0.01% (v/v) 
0.0007% (v/v) 
dH2O 
Acrylamide (30%) 
0.5 M TRIS/SDS pH 6.8 
APS 
Temed 
SDS running buffer 25 mM 
0.1% (w/v) 
200 mM 
TRIS Ultra 
SDS 
Glycine 
Coomassie staining solution 45% (v/v) 
10% (v/v) 
0.25% (w/v) 
45% (v/v) 
Methanol 
Acetic acid (99%) 
Brilliant Blue R 
dH2O 
Coomassie destain 45% (v/v) 
10% (v/v) 
45% (v/v) 
Methanol 
Acetic acid 
dH2O 
Western blot transfer buffer 25 mM 
190 mM 
20% (v/v) 
TRIS Ultra 
Glycine 
Methanol 
6x DNA loading dye 50% (v/v) 
50% (v/v) 
0.4% (w/v) 
TAE 
Glycerol 
Orange G 
2.4 Primer 
Primer designation Primer sequence (5’-3’) 
FAP 5.1 CAGGTACAGCTGAAGCAGTCT 
FAP 3.1 ACCACCTCCGGATCCAGCCCGTTTTATTTC 
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FAP 5.2 CCCATGGGCCAGGTACAGCTGAAGCAG 
FAP 3.2 GCCATGGGTGATCCACCACCTCCGGATCCAGC 
pEE12_4_fwd CTTGACACGAAGCTTGCCGCCACCATGAACTGG 
pEE12_4_rev ATGATCAATGAATTCTTAGTGATGGTGATGGTGATGTGA 
141106_FWD_BstBI CTTCGCGACGTACGTTCGAAGCCGCCACCATGAACTGG 
141106_REV_EcoRI TGATTATGATCAATGAATTCTTAGTGATGGTGATGGTGATGTGA 
pEE12_4_ext_FWD GTTCCTTTCCATGGGTCTTTTCTGC 
pEE12_4_ext_REV CAAGTAAAACCTCTACAAATGTGGTATGGC 
Seq5_aFAP_end AGTAGGGAGCTTCCGTACACGTTCG 
Seq5_aCD33_end ACGTTCGGTGGAGGCACCAAGCT 
2.5 Plasmids and bacteria 
2.5.1 Plasmids 
pEAK8 Edge BioSystems, Gaithersburg, USA 
pEAK8-antiCD33-antiCD3 pEAK8 with knocked out BamHI restriction site in 
backbone 
pEAK8-antiCD33-mGITRL with antiCD33 and mGITRL, c-myc- and 6xHis-Tag 
pEAK8-antiFAP with antiFAP scFv, c-myc- and 6xHis-Tag 
pEAK8-antiFAP-hGITRL with antiFAP and hGITRL, c-myc- and 6xHis-Tag 
pEAK8-antiFAP-mGITRL with antiFAP and mGITRL, c-myc- and 6xHis-Tag 
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pEE12.4 Lonza, Slough, UK 
pEE12.4-antiCD33-mGITRL with antiCD33 and mGITRL, c-myc- and 6xHis-Tag 
pEE12.4-antiFAP with antiFAP scFv, c-myc- and 6xHis-Tag 
pEE12.4-antiFAP-hGITRL with antiFAP and hGITRL, c-myc- and 6xHis-Tag 
pEE12.4-antiFAP-mGITRL with antiFAP and mGITRL, c-myc- and 6xHis-Tag 
pEYFP N1 MB36 pEYFP N1 vector (Clontech Laboratories, Mountain 
View, USA) containing the sequence for the anti-FAP 
antibody MO36. Provided by K. Pfizenmaier. 
2.5.2 Media for bacteria 
LB medium 10 g 
5 g 
5 g 
1 l 
 
Tryptone 
Yeast extract 
NaCl 
dH2O 
heat sterilize medium 
LB-Amp   LB medium with 100 µg/mL ampicillin (Sigma, St. Louis, USA) 
added after sterilization 
LB-Amp plates
  
LB-Amp with 1.5% (w/v) Difco agar (BD, Sparks, USA) added 
before sterilization 
2.5.3 Bacterial strains 
One shot TOP10 Chemically Competent E. coli, Invitrogen, Carlsbad, USA 
Fusion-Blue Competent Cells (E. coli), Clontech Laboratories, Mountain View, USA 
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2.6 Cell culture and media 
2.6.1 Cell culture media 
All cells were cultivated at 37 °C in a 5% CO2 incubator. Cell culture reagents were 
purchased from Sigma-Aldrich (St. Louis, USA), SAFC Biosciences (Lenexa, USA), 
Gibco/Invitrogen (Carlsbad, USA). 
D10  
 
 
10% (v/v) 
1% (v/v) 
Dulbecco’s Modified Eagle Medium, with L-
glutamine, 4500 mg/l D-Glucose, 110 mg/l Sodium 
Pyruvate 
heat inactivated FBS 
Penicillin-Streptomycin (stock solution 5000 units/ml 
penicillin, 5000 µg/ml streptomycin) 
D10 + G418  
200 µg/ml 
D10 
G418 
D10 + Puromycin  
3 µg/ml 
D10 
Puromycin 
D10sel  
 
 
10% (v/v) 
1% (v/v) 
2% (v/v) 
Dulbecco’s Modified Eagle Medium, 4500 mg/l D-
Glucose, without L-glutamine, without Sodium 
Pyruvate 
Dialyzed, heat inactivated FBS 
Penicillin-Streptomycin 
GS supplements (50x) 
D5sel  D10sel with only 5% FBS 
Dsarcoma  
10% (v/v) 
1% (v/v) 
D-MEM/F-12 (1:1) 
heat inactivated FBS 
Penicillin-Streptomycin 
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EXC  
0.2% (v/v) 
2% (v/v) 
1% (v/v) 
EX-CELL NS0, serum free, without L-Glutamine 
SynthChol NS0 Supplement (500x) 
GS supplement (50x) 
Penicillin-Streptomycin 
R10  
10% (v/v) 
1% (v/v) 
RPMI 1640 Medium with Glutamax 
heat inactivated FBS 
Penicillin-Streptomycin 
R10 + 
Puromycin/HTsuppl
 
1% (v/v) 
10 µg/ml 
R10 
HT Supplement (100x) 
Puromycin 
R10 + β-m  
50 uM 
R10 
β-mercaptoethanol 
R10p + Zeocin  
200 µg/ml 
R10 with preabsorbed FBS as described in 2.12.1 
Zeocin 
2.6.2 Cell lines 
Name Culture medium Description/origin 
NS0 D10 Lonza, Slough, UK 
NS0 transfected clones D10sel 
50% D5sel & 50% EXC 
Transfections performed as 
described in section 2.12.6 
HEK 293 mGITRL-Fc  R10p + Zeocin Provided by H. Nishikawa 
HEK 293 parental (EBNA) D10 + G418 Provided by F. Wurm 
HEK 293 mFAP D10 + Puromycin Produced in-house 
CHO parental R10 Provided by Ludwig Institute for 
Cancer Research, New York 
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CHO hCD33 R10 + Puromycin/HT 
suppl. 
CHO cells expressing full length 
human CD33 antigen (Bauer et 
al., 2004) 
CMS5a parental R10 + β-m Provided by H. Nishikawa 
CMS5a hGITR R10 + β-m CMS5a expressing the 
extracellular domain of human 
GITR; provided by H. Nishikawa 
CMS5a mGITR R10 + β-m CMS5a expressing the 
extracellular domain of murine 
GITR; provided by H. Nishikawa 
CT26 R10 + β-m Murine colon carcinoma line; 
provided by H. Nishikawa 
LM8 Dsarcoma Murine osteosarcoma line; 
provided by B. Fuchs.  
2.7 Mice 
6 to 8 weeks female BALB/cHsd1 and 7 weeks old male C3H/Hsd mice were 
purchased from Harlan Laboratories (Venray, Netherlands). Mice were used within 2 
months of delivery. 
2.8 Software 
BIAcore T100 Evaluation Software V 2.0 (GE Healthcare, Uppsala, Sweden) 
CellQuest Pro 4.0.2 (BD Biosciences, San Jose, USA)  
FACSdiva (BD Biosciences, San Jose, USA) 
FlowJo 7.2.5 (Tree Star, Ashland, USA) 
GraphPad Prism V 5.01 for Windows (GraphPad Software, San Diego, USA) 
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Microsoft Office Excel 2003 (Microsoft, Redmond, USA) 
Microsoft Office Word 2003 (Microsoft, Redmond, USA) 
SigmaPlot 11.0 (Systat Software, Chicago, USA) 
2.9 Bacterial methods 
2.9.1 Growth of bacteria in suspension 
For small scale cultivation, a 14 ml polypropylene round-bottom tube with 3 ml of LB-
Amp medium was inoculated with TOP10 from a glycerol stock. For medium size 
cultivation, 200 ml of LB-Amp medium was inoculated with a small amount of TG1 from 
a glycerol stock in a 500 ml Erlenmeyer flask. Bacteria were cultivated o/n at 37 °C in a 
shaker (200 rpm). 
2.9.2 Growth of bacteria on agar plates  
50 μl bacterial suspension resulting from freshly transformed E. coli cells or from 
glycerol stock diluted in LB-Amp medium was plated on LB-Amp agar plates. Bacteria 
were cultivated o/n at 37 °C. 
2.9.3 Transformation of competent E. coli cells 
The mix resulting from a ligation or recombination reaction was added to 1 vial (50 μl) 
of Fusion-Blue or TOP10 competent E. coli cells and incubated 15-30 min on ice. Cells 
were heat-shocked for 45 s at 42 °C and directly placed one ice for 1 min. 450 μl SOC 
medium (Invitrogen, Carlsbad, USA) was added followed by shaking for 1 h at 250 rpm 
at 37 °C. Finally 50 μl were plated on LB-Amp plates. 
2.9.4 Glycerol stocks of bacteria 
850 μl of o/n bacteria culture was transferred to a 2 ml cryotube and 150 μl of glycerol 
was added to yield a final glycerol concentration of 15% v/v. After thorough mixing, the 
tube was stored at -80 °C. 
2 Material and Methods  25
2.10 Molecular biology techniques 
2.10.1 Preparation of plasmid DNA from E. coli 
Small amounts of plasmid DNA required as PCR template were isolated from TOP10 
E. coli carrying the target plasmid. The DNA was extracted from the bacteria using the 
QIAprep Spin Miniprep Kit according to the manufacturer’s protocol. Molecular biology 
grade water (Sigma, St. Louis, USA) was used for elution of DNA from the columns. 
Large amounts of plasmid DNA required for cloning and for transient and stable 
transfections of NS0 cells were isolated from TOP10 strains carrying the plasmid. The 
DNA was extracted using the QIAGEN Plasmid Maxi Kit according to the 
manufacturer’s protocol. Sterile molecular biology grade water (Sigma, St. Louis, USA) 
was used to redissolve the DNA. 
2.10.2 Determination of DNA concentration 
Concentration of the prepared plasmid DNA was determined by measuring the 
absorbance at 260 nm and additionally at 280 nm to account for impurities. For a pure 
DNA solution, an A260nm of 1 corresponded to a concentration of 50 µg/ml. DNA with a 
A260nm/A280nm of 1.8-2 was considered as pure.  
2.10.3 Agarose gel electrophoresis 
For analytical or preparative separation of DNA fragments, 0.7-1% (w/v) agarose 
(Promega, Madison, USA) gels were prepared with TAE buffer and 10 µg/ml ethidium 
bromide (Sigma, St. Louis, USA). The samples were mixed with a 6x DNA loading dye. 
100 bp and 1 kb DNA ladder (New England BioLabs, Ipswich, USA) were used as size 
standards at 0.5 μg per lane. A voltage of 80 to 100 V was applied to the gels. After 
electrophoresis DNA was detected via its fluorescence under UV light and a picture 
was recorded for documentation purposes.  
2 Material and Methods  26
2.10.4 Amplification of DNA by Polymerase Chain Reaction 
Oligonucleotide primers specific for the DNA fragments were designed and purchased 
from MWG Biotech AG (Ebersberg, Germany) or Microsynth AG (Balgach, 
Switzerland). All primers are listed in section 2.4.  
For amplification of the DNA of interest the Phusion High-Fidelity DNA Polymerase 
(Finnzymes, Espoo, Finland) was used. 10 mM stock of dNTPs was purchased from 
Invitrogen (Carlsbad, USA) and GC buffer from the polymerase kit was used.  
 
Reaction conditions were as follows:  
 Template DNA  10-100 ng 
 Forward primer  25 pmol 
 Reverse primer  25 pmol 
 dNTPs     200 μM 
 Phusion polymerase 1 U 
 5x GC buffer   10 μl 
 dH2O     adjust volume to 50 μl 
Cycling conditions: 
Initial denaturation  98 °C  3 min 
Denaturation    98 °C   10 s 
Annealing     69.5 °C 20 s 
Elongation     72 °C  20 s back to step 2, 30 cycles 
Final elongation   72 °C  10 min 
2.10.5 Digestion of DNA with restriction endonucleases 
Restriction endonucleases were purchased from New England BioLabs (Ipswich, USA) 
for digestion of DNA. Reaction buffers, concentration of enzymes and DNA, incubation 
times and temperatures were chosen according to the manufacturer’s instructions. 
When working with PvuI, the enzyme was heat inactivated for 20 min at 80 °C after 
digestion.  
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2.10.6 Purification of PCR products and plasmid fragments 
Fragments resulting from digestion or PCR were analyzed by agarose gel 
electrophoresis. The correct fragment was determined by comparison with the 
appropriate size standard, excised from the gel and purified using the QIAquick Gel 
Extraction Kit according to the manufacturer’s protocol. Molecular biology grade water 
was used to elute the DNA from the columns.  
2.10.7 Ligation of DNA 
The previously digested DNA vector was dephosphorylated prior to the ligation 
reaction. This was achieved by using 2 U of Shrimp Alkaline Phosphatase (Roche 
Diagnostics, Mannheim, Germany) for 100 ng of DNA with dephosphorylation buffer 
provided by the manufacturer. The mix of 11 μl was incubated for 15 min at 37 °C and 
subsequently for 20 min at 65 °C to inactivate the Alkaline Phosphatase. In parallel, the 
enzymes from the digested insert were heat inactivated under the same conditions. 
The DNA was used without further purification and ligation was performed with the 
Rapid DNA Ligation Kit. In one ligation reaction, 50 ng of insert and 100 ng of plasmid 
were mixed with DNA dilution buffer from the kit, 20 μl T4 DNA ligation buffer and 10 U 
T4 DNA Ligase and incubated for 30 min at RT. After the ligation reaction 2-4 μl of the 
mix was immediately used for transformation of E. coli cells.  
2.10.8 Cloning by recombination of DNA 
The In-Fusion Dry-Down PCR Cloning Kit was used for cloning of the fusion proteins 
by recombination. 170 ng linearised vector and 60 ng insert resulting from the PCR 
were mixed at a 1:2 molar ratio in 10 μl dH2O. This was added to the provided tube 
containing the ready-to-use reaction powder and incubated for 30 min at 42 °C. 
Subsequently 40 μl TE buffer was added and 2.5 μl of the mix was used for immediate 
transformation of competent E. coli cells.  
2.10.9 Colony PCR 
To verify insertion of the insert into the plasmid, a colony PCR reaction was carried out 
using the REDTaq ReadyMix. A small amount of the colony was mixed with the kit, 
primers and dH2O. After the reaction the mix was analyzed on an agarose gel.  
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Reaction conditions were as follows:  
 Template    a tip of a colony 
 Forward primer  10 pmol 
 Reverse primer  10 pmol 
 RedTaq Mix   10 μl 
 dH2O     adjust volume to 20 μl 
Cycling conditions: 
Initial denaturation  94 °C  2 min 
Denaturation    94 °C   20 s 
Annealing     60 °C  30 s 
Elongation     72 °C  75 s back to step 2, 35 cycles 
Final elongation   72 °C  7 min 
2.10.10 Sequencing 
Successful cloning of all plasmids was confirmed by sequencing of the part of the 
plasmid containing the fusion proteins as well as the flanking regions. The sequencing 
reactions were performed by MWG Biotech AG (Ebersberg, Germany) or Microsynth 
AG (Balgach, Switzerland). The primers used for sequencing are pEE12_4_ext_FWD, 
Seq5_aFAP_end and Seq5_aCD33_end.  
2.10.11 Cloning strategies of fusion proteins 
2.10.11.1 Cloning of pEAK8 vectors with fusion proteins 
pEAK8-antiCD33-antiCD3 vector (Thiel et al., 2010) was used as starting vector. The 
vector contains an expression cassette consisting of Kozak-Start-Leader-antiCD33-
Linker-antiCD3-c-myc-6xHis-Stop. The BamHI restriction site within the backbone has 
previously been knocked out and the cassette contains c-myc and 6xHis tags. The 
fusion proteins are linked by a G4S linker (GGGGS).  
Sequences containing a GGGGS (G4S) linker, NcoI restriction site and extracellular 
human or murine GITR ligand domains (amino acids L49 to S177 for hGITRL and S43 
to S173 for mGITRL) flanked on both sides by a BamHI restriction site were sequence 
optimized and synthesized by GENEART (Regensburg, Germany) 
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The antiFAP single chain antibody (antiFAP scFv) clone MO36 which recognizes both 
murine and human FAP (Brocks et al., 2001) was kindly provided by K. Pfizenmaier 
(Institute of Cell Biology and Immunology, University of Stuttgart, Germany) in the 
pEYFP N1 MB36 plasmid. 
The antiCD33 single chain antibody in the pEAK vector originates from the murine 
hybridoma M195 secreting an anti-human CD33 IgG (HB-10306, ATCC/ LGC 
Standards, Molsheim, France).  
pEAK8-antiCD33-antiCD3 and the GENEART synthesized constructs Linker-mGITRL 
and Linker-hGITRL were digested with BamHI, resulting in fragments with sticky ends 
and removal of Linker-antiCD33 from the vector. Digests were separated by agarose 
gel electrophoresis, purified by gel extraction and the inserts were ligated into the 
vector. Successful insertion and correct orientation of the inserts was analyzed by NcoI 
digestion of purified plasmid DNA of some clones. Hereby produced plasmids pEAK8-
antiCD33-mGITRL and pEAK8-antiCD33-hGITRL were digested with NcoI to release 
the antiCD33-linker insert.  
antiFAP sequence was amplified by PCR using primer pairs FAP 5.1 and FAP 3.1 with 
vector pEYFP N1 MB36 as a template. After gel extraction, the amplified sequence 
was used as a template for a second round of PCR with primer FAP 5.2 carrying an 
NcoI restriction site and primer FAP 3.2 introducing the BamHI-Linker-NcoI sequence. 
Gel purified product was digested with NcoI and ligated into the prepared plasmids, 
leading to plasmids pEAK8-antiFAP-mGITRL and pEAK8-antiFAP-hGITRL. Successful 
insertion and correct orientation of the inserts was analyzed by BamHI digestion of 
plasmid DNA. Production of pEAK8-antiFAP was achieved by digesting pEAK8-
antiFAP-mGITRL with BamHI and religating the vector without any insert. Successful 
cloning was analyzed by BamHI digestion of DNA from resulting clones. 
2.10.11.2 Cloning of pEE12.4 plasmid for antiFAP-mGITRL production 
The sequence Kozak-Start-Leader-antiFAP-Linker-mGITRL-c-myc-6xHis-Stop was 
transferred from the vector pEAK8 to pEE12.4 as follows.  
Vector pEAK8-antiFAP-mGITRL was digested with XhoI and NotI. Resulting fragments 
were separated on an agarose gel and the 1569 bp fragment was extracted from the 
gel. This was used as a template for PCR amplification with primers pEE12_4_fwd 
(carrying a HindIII restriction site) and pEE12_4_rev (carrying an EcoRI restriction site). 
The resulting amplified fragment contained the sequence Kozak-Start-Leader-antiFAP-
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Linker-mGITRL-c-myc-6xHis-Stop with flanking regions of the pEAK8 vector. The 
produced insert and the pEE12.4 vector were digested with EcoRI and HindIII, followed 
by heat inactivation of the enzymes. A short digestion time of 90 min was chosen to 
achieve partial digestion of the insert since a second HindIII restriction site is present 
within the antiFAP sequence. Ligation and transformation were performed as described 
in sections 2.10.7 and 2.9.3. DNA isolated from 10 clones was digested with BamHI to 
check for presence of pEE12.4 backbone. 2 positive clones were subjected to PCR 
with the primer pairs pEE12_4_fwd and pEE12_4_rev using Phusion polymerase. 
Based on electrophoretical separation of the digestion and PCR products, the 2 clones 
showed the pEE12.4 backbone and correct size of insert.  
2.10.11.3 Cloning of pEE12.4 plasmids for antiFAP-hGITRL, antiCD33-mGITRL 
and antiFAP production 
The sequences Kozak-Start-Leader-antiFAP-Linker-hGITRL-c-myc-6xHis-Stop, Kozak-
Start-Leader-antiFAP-c-myc-6xHis-Stop and Kozak-Start-Leader-antiCD33-Linker-
mGITRL-c-myc-6xHis-Stop were transferred from vector pEAK8 to pEE12.4 by 
recombination as described below.  
The target vector pEE12.4 was digested with EcoRI and BstBI. The inserts from the 
pEAK8 plasmids were amplified using the primer pair 141106_FWD_BstBI and 
141106_REV_EcoRI. These primers contain a BstBI and EcoRI restriction site, 
respectively, and were designed to share 20 bp of homology at their 5’ end with the 
linearization site of the pEE12.4 backbone. These homologous regions allow for the 
recombination reaction when insert and linearized vector are incubated together 
according to the procedure described in section 2.10.8. Successful transfer of the insert 
was checked by colony PCR with primers pEE12_4_ext_FWD and pEE12_4_ext_REV 
that bind to the backbone of the pEE12.4 vector close to the polylinker.  
2.11 Biochemical techniques 
2.11.1 Dot blot with cell culture supernatant 
10 μl of cell culture supernatant was transferred to PROTRAN nitrocellulose membrane 
(0.45 um pore size, Whatman, Dassel, Germany), blocked with 10% MPBS and 
incubated with anti-c-myc (1:5000 in 2% MPBS) and anti-mouse/HRP (1:1000 in 2% 
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MPBS). Staining steps were for 1 h at room temperature and were followed by a 10 
min washing step in 0.1% PBST. Detection reaction was performed with Amersham 
ECL Western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK). 
2.11.2 Purification of fusion proteins 
One volume of sterile filtered cell culture supernatant was mixed with one volume of 
sterile PBS and the mix was incubated with washed TALON Metal Affinity Resin 
(Clontech Laboratories, Moutain View, USA) at least 2 hours at 4 °C on a roller bed. 2 
ml of bead suspension was used per 300 ml of cell culture supernatant. Beads were 
previously equilibrated by adding 20 volumes of PBS to the bead suspension, 
centrifugating at 300g and discarding the supernatant. After incubation, the supernatant 
and bead suspension was poured into a 20 ml Econo-Pac column (Bio-Rad, Hercules, 
USA) to collect the resin. Flow-through was accelerated with a suction pump at the exit 
of the column. The flow-through was collected and circulated through the column twice. 
The column was washed with 200 ml 0.1% PBST and 200 ml PBS. The fusion protein 
was eluted from the column in 4 fractions of 1ml PBS-150 mM Imidazol (Sigma-Aldrich, 
St. Louis, USA). The eluate was dialyzed o/n against PBS at 4 °C with a 10 kDa cut-off 
membrane (SnakeSkin Pleated Dialysis Tubing, Thermo Scientific, Rockford, USA). 
Proteins were stored at 4 °C for up to one week for further analysis. 
2.11.3 Purification of mGITRL-Fc 
One volume of sterile filtered cell culture supernatant was mixed with one volume of 
sterile PBS and the mix was incubated with washed protein A Agarose beads Fast 
Flow (Millipore, Temecula, USA) at least 2 hours at 4 °C on a roller bed. 1 ml of bead 
suspension was used per 1000 ml of cell culture supernatant. After incubation, resin 
was collected in a 20 ml Econo-Pac column washed with 100 ml 0.1% PBST and 100 
ml PBS. The fusion protein was eluted from the column in 5 fractions of 900 μl 50 mM 
glycine pH 2 in tubes containing 100 μl antibody neutralization buffer (1 M TRIS, 1.5 M 
NaCl, 1 mM EDTA, pH 8). The eluate was dialyzed o/n against PBS at 4 °C with a 10 
kDa cut-off membrane. Proteins were stored at 4 °C for up to one week for further 
analysis. 
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2.11.4 SDS Polyacrylamide Gel Electrophoresis 
20 μl of the eluate was mixed with 5 μl of 5x SDS loading buffer and denatured for 5 
min at 95 °C. During electrophoresis, the samples were first focussed in a 5% stacking 
gel at 40 mA and subsequently separated according to their relative molecular mass in 
a 12% running gel at 70 mA. Dual Color Precision Plus Protein Standard (Bio-Rad, 
Hercules, USA) served as size standard and SDS running buffer as described was 
used. Gels were stained with Coomassie staining solution and destained with 
Coomassie destain until the protein bands were clearly visible. For documentation, gels 
were scanned (CanoScan LiDE 70, Canon, Amstelveen, Netherlands). 
2.11.5 Immunochemical detection of proteins by Western blot 
After electrophoretic separation of the proteins, the unstained gel, two pieces of Extra 
Thick Blot Paper (Bio-Rad, Hercules, USA) and PROTRAN nitrocellulose membrane 
(0.45 um pore size) were equilibrated in Western blot transfer buffer. These were 
assembled on a Trans-Blot SD apparatus and proteins were blotted for 30 min at 12 V 
per gel. For detection of His-tagged proteins, the membrane was blocked with 10% 
MPBS for 1 h at RT or o/n at 4 °C. Then, the membrane was incubated with 
monoclonal mouse PentaHis antibody (1:1000 in 2% MPBS) for 1 h, washed for 10 min 
with 0.1% PBST and incubated for 1 h with anti-mouse/HRP antibody (1:1000 in 2% 
MPBS). Control staining were performed with anti-His/anti-mouse/HRP, anti-
mouse/HRP alone or peroxidase-conjugated anti-bovine antibody (1:1000 in 2% 
MPBS). After one washing step for 10 min with 0.1% PBST, detection of the protein 
was performed using Amersham ECL Western Blotting Detection Reagent. All steps 
occurred at room temperature. 
2.11.6 Determination of protein concentration 
Protein concentrations were determined by a colorimetric method using the BCA 
Protein Assay Kit following the manufacturer’s instructions. 10 μl of samples was 
measured in a 200 μl volume of working reagent. Whenever necessary, the samples 
were diluted prior to analysis. AffiniPure F(ab’)2 Fragment Goat anti-Mouse IgG was 
used as standard. 
2 Material and Methods  33
2.11.7 Concentration and storage of fusion proteins 
The fusion proteins were concentrated with Centriprep centrifugal filter devices Ultracel 
YM-10 and YM-30 (Millipore, Billerica, USA) depending on the molecular weight of the 
construct. The volume of the constructs was adjusted to a final concentration of 1 
mg/ml in PBS-10% glycerol. The samples were sterile filtered with a syringe (5 ml 
Omnifix, Braun, Melsungen, Germany) and 0.22 µm disposable filter (Millex-GV, 
Millipore, Billerica, USA) and stored at -20 °C or -80 °C.  
2.11.8 Size Exclusion Chromatography 
Purified antiFAP, antiFAP-mGITRL and anti-FAP-hGITRL constructs were analyzed by 
size exclusion chromatography on a Superose 12 PC 3.2/30 column (GE Healthcare, 
Uppsala, Sweden) coupled to a HP 1100 Series HPLC System. The column was 
equilibrated with PBS and calibrated by injection with standards (Sigma, St. Louis, 
USA) diluted in PBS as follows: 0.4 mg/ml phosphorylase (97 kDa), 0.2 mg/ml bovine 
serum albumin (66 kDa), 0.2 mg/ml ovalbumin (45 kDa) and 0.2 mg/ml cytochrome c 
(12 kDa). The constructs were diluted in PBS to 0.2 mg/ml and 10 μl were applied to 
the column at a flow rate of 50 μl/min. All injections were performed at least twice.  
2.11.9 Surface Plasmon Resonance binding assays 
Binding assays were performed with a BIAcore T100 (GE Healthcare, Uppsala, 
Sweden) at 25 °C. A CM5 sensor chip (GE Healthcare, Uppsala, Sweden) was 
activated with NHS/EDC for 7 min at a flow rate of 5 µl/min. Recombinant human 
GITR-Fc (R&D Systems, Minneapolis, USA) (10 µg/ml) was immobilized in 10 mM 
sodium acetate buffer (pH 5.0) on the chip by amine coupling, resulting in 770 RUs 
after ethanolamine treatment (7 min). Recombinant murine GITR-Fc (R&D Systems, 
Minneapolis, USA) (10 µg/ml) was coated on a separate flow cell in the same buffer, 
resulting in 480 RUs. For the binding assays the analytes were dialysed against HBS-
EP buffer (10 mM HEPES pH7.4, 150 mM NaCl, 3 mM EDTA and 0.005% surfactant 
P20, GE Healthcare, Uppsala, Sweden) and dilutions thereof were injected over the 
chip at a flow rate of 30 µl/min for 10 min. Each series of dilutions was measured twice. 
Washing was done by injecting 10 mM Glycine-HCl pH 2.2 twice for 60 s. 
Kinetic data were analysed with BIAcore T100 Evaluation Software V 2.0. Double-
referenced association and dissociation phase data on human GITR were globally fit to 
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a simple 1:1 interaction model. Affinity on murine GITR was calculated by fitting of the 
1:1 Langmuir binding model to the steady-state plateaus. 
2.12 Cell culture techniques and immunobiological methods 
2.12.1 Cultivation of cell lines 
All cells were cultured at 37 °C and 5% CO2 in media described in section 2.6.1. Most 
adherent cell lines were detached from cell culture flasks by incubation with PBS-1 mM 
EDTA. LM8 cells were detached by 5 min incubation with Trypsin-EDTA solution 
(Gibco/Invitrogen, Carlsbad, USA) and cultivation medium was then added for 
neutralization of trypsin. All cells were flushed off the flask with a pipette, centrifugated 
for 5 min at 1500 rpm, resuspended in cultivation medium and 5 to 10% was reseeded 
in T flasks. 
2.12.2 Large scale cultivation of NS0 cells 
Stable NS0 clones were either grown in T300 cell culture flasks (inoculation of 60 x 106 
cells in 300 ml medium) or FibraStage bottles (inoculation of 200 x 106 in 500 ml 
medium). Cultivation medium (50% D5sel and 50% EXC) was replaced every 5 days. 
Inoculation parameters for the FibraStage were top_hold 30 s, up 2 mm/s, bottom_hold 
0 s, down 2 mm/s and cultivation parameters were top_hold 20 s, up 1.5 mm/s, 
bottom_hold 60 s, down 1.5 mm/s. 
2.12.3 Cultivation of HEK 293 mGITRL-Fc cells 
FBS was preabsorbed prior to cultivation of HEK 293 mGITRL-Fc cells to remove 
bovine IgG. 2 ml protein G Agarose beads Fast Flow (Millipore, Temecula, USA) were 
washed with 50 ml PBS, centrifugated at 300g and supernatant was discarded. 50 ml 
of heat-inactivated FBS was incubated o/n at 4 °C with 1 ml of washed beads on a 
roller bed. Beads were collected in an Econo-Pac column and flow-through was used 
for preparation of the cell culture medium. Bovine IgGs were eluted from the column 
with 5 bed volumes of 50 mM glycine pH 2. Column was equilibrated with 20 bed 
volumes of PBS for preabsorption of next FBS sample. 
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HEK 293 mGITRL-Fc cells were cultivated in R10p + Zeocin medium and treated as 
described in section 2.12.1. 
2.12.4 Determination of cell number and viability 
Cell number, size distribution and viability of cell lines and murine splenocytes were 
determined with the help of CASY Cell Counter + Analyzer System Model TT (Roche 
Innovatis, Bielefeld, Germany). 50 μl of sample cell suspension was mixed with 10 ml 
of CASYton solution and analyzed with the cell counter. The method is based on 
Electrical Current Exclusion which measures the volume and viability of the cell in a 
dye-free setting. 
2.12.5 Transient expression of fusion proteins 
Correct cloning of the fusion proteins was assessed by transient transfection of HEK 
293 EBNA cells. 8 µg DNA and Fugene6 (Roche, Mannheim, Germany) at a ratio 
reagent:DNA of 3:1 were incubated for 1 hour in 800 μl DMEM at room temperature 
and subsequently added to a 50% confluent T75 cell culture flask in D10 medium 
without FBS. The following day 10% FBS (v/v) was added to the culture. The 
supernatant was harvested after 3 to 5 days, filtrated and analyzed. Presence of 
construct in the supernatant was assessed by flow cytometry as described in section 
2.12.7.  
2.12.6 Stable expression of fusion proteins 
Stably transfected NS0 cell lines were generated by electroporation according to the 
protocol provided by Lonza. Briefly, 40 µg sterile DNA was digested for 4 hours with 
PvuI at 37 °C in a final volume of 100 μl and the enzyme was subsequently heat 
inactivated (20 min, 80 °C). 1 x 107 NS0 cells were resuspended in 700 μl DMEM in an 
electroporation cuvette (4 mm gap cuvette, BTX Harvard Apparatus, Holliston, USA), 
DNA was added and a single pulse of 250 V, 400 µF was delivered. Cells were plated 
at serial dilutions in D10 in flat bottom 96-well plates. The next day D10sel medium was 
added. Four to six weeks later the supernatants were screened by dot blot. Positive 
clones were transferred to a 24-well plate in 1 ml D10sel. In a weekly fashion, the 
clones were tested for fusion protein expression and positive clones were transferred 
first into a 6-well plate and subsequently into T75 cell culture flasks.  
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2.12.7 Flow cytometry analysis 
Supernatants of transient expression or purified fusion proteins from stable expression 
were characterized by flow cytometry. All constructs were tested for binding on the 
following target cell lines: HEK 293 parental, HEK 293 mFAP, CHO parental, CHO 
hCD33, CMS5a parental, CMS5a mGITR and CMS5a hGITR. Purified construct was 
also tested for binding to naïve and activated murine splenocytes. 1 x 106 cells/well 
were stained with supernatant (100 ul, undiluted) or purified protein (10 µg/ml in 200 μl 
FACS buffer). Detection was performed with Penta-His (1:200) and anti-mouse Fcγ PE 
(1:200) for HEK 293 and CHO cell lines and with Penta-His (1:200), anti-mouse IgG 
(H+L) biotin (1:200) and streptavidin PE (1:200) for CMS5a cell lines and splenocytes. 
Incubations were performed in 200 μl staining volume (unless otherwise specified) for 
30 min at 4 °C and were separated by two washing steps with FACS buffer. Murine 
splenocytes were co-stained with anti-mouse CD3 PE-Cy7, CD4 APC-Alexa750 and 
CD8-PerCP.  
LM8 cells from cultivation in tissue culture flasks and freshly digested LM8 tumor cell 
suspension were stained with the fusion proteins as described above. Detection was 
performed with antiHis-biotin (1:100) and streptavidin PE (1:200). Control staining was 
performed with ESC11 IgG (10 µg/ml), vF19 (10 μg/ml) and anti-human F(ab')2 PE.  
Flow cytometry analysis was performed using FACScan and FACSCanto II cytometers 
with FACSdiva software. 
2.12.8 Tetramer staining of blood lymphocytes 
Blood samples from BALB/c mice were stored in FACS buffer until tetramer staining. 
Samples were stained with 12 µg/ml PE-labeled H-2Ld/AH-1138-147 tetramer for 10 min 
at 37 °C before additional incubation with CD8a FITC antibody for 15 min at 4 °C. After 
erythrocyte lysis with 1 ml BD FACS Lysing Solution (BD Biosciences, San Diego, 
USA), 1 x 104 CD8+ T cells were measured on a FACScan cytometer and percentage 
of tetramer-positive cells among CD8+ T cells was determined. 
2.12.9 Flow cytometric determination of apparent affinity of fusion 
proteins to FAP 
For affinity studies, antiFAP-hGITRL, antiFAP-mGITRL and antiFAP fusion proteins 
were serially diluted with FACS buffer. Fusion protein at various concentrations was 
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incubated with 3 x 105 HEK 293 mFAP cells. Detection was performed with Penta-His 
(1:100), anti-mouse IgG (H+L) biotin (1:100) and streptavidin PE (1:200). All incubation 
steps were performed for 1 h at 4 °C in a 100 μl final volume. For each dilution, 
fluorescence intensity of 1 x 104 cells was measured with a FACScan supported by 
CELLQUEST software. Mean fluorescence intensity of the live population of each 
sample was converted to percentage of maximum binding for each fusion protein and 
plotted against fusion protein concentration. For determination of apparent affinity of 
antiFAP to FAP, half maximal binding concentration (KDapp) was calculated with the 
help of a regression line connecting the 2 measurements closest to 50% of maximal 
binding. All experiments were done 3 times with different batches of antibodies. 
2.12.10 Immunohistochemistry 
6 μm frozen sections of tumors were fixed for 10 min in cold acetone, washed in PBS 
and blocked 10 min with PBS-1% FBS. The sections were then incubated with 10 
μg/ml ESC11, ESC14 or human κ IgG isotype control for 1 h at RT and subsequently 
with anti-human (H+L) biotin (1:80) in PBS with 2% normal mouse serum (Jackson 
ImmunoResearch, Suffolk, UK) for 45 min. Incubation for 30 min with VECTASTAIN 
ABC reagent (Vector Laboratories, Burlingame, CA) supplemented with 2% normal 
mouse serum was followed by staining with ImmPACT DAB substrate solution (Vector 
Laboratories, Burlingame, CA) for 10 min. After rinsing with tap water, sections were 
counterstained with Mayer’s Haematoxylin solution (Sigma-Aldrich, St. Louis, USA), 
washed and bedded in glycerin-gelatin (Kantonsapotheke, Zürich, Switzerland). 
Separate tumor sections were stained with hematoxylin and eosin according to 
standard procedure. All slides were examined with a Polyvar 2 microscope. 
2.12.11 Purification of T cell subsets 
Spleens from naïve BALB/c or C3H mice were crushed, filtered and depleted of 
erythrocytes by ACK lysis (ACK Lysing Buffer, Invitrogen, Carlsbad, USA). T cell 
subsets were purified using MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s protocol. Positive selection was performed 
with anti-mouse CD8 microbeads. CD4+25+ regulatory T cells and CD4+25- effector T 
cells were separated with the CD4+25+ Regulatory T Cell Isolation Kit. Purity of the 
resulting populations was analyzed by flow cytometry (anti-mouse CD4 FITC, CD8a 
FITC, CD25 PE).  
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2.12.12 CFSE labelling of T cells 
Target CD8+ or CD4+25- cells were labelled with 2.5 μM 5,6-carboxyfluorescein 
diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, USA) in PBS for 6 min 
in the dark at 37 °C. Cells were subsequently washed three times with 10 ml D10 
medium. Cell assays were performed in D10 medium in a 200 μl final volume in 96-well 
flat bottom cell culture plates. 
2.12.13 Activation of T cells for FACS analysis 
Fresh mouse BALB/c splenocytes were stimulated for 2 days with antiCD3/CD28 
microbeads (ratio 5:1). 8 x 106 cells per well were cultivated in 5 ml R10 in 6-well-
plates. On day 2, the beads were removed magnetically before antibody staining. 
2.12.14 Proliferation assays 
In BALB/c proliferation assays, 1 x 105 target CD8+ or CD4+25- cells were incubated 
with parental or mFAP transfected HEK 293 cells (2 x 104) in the presence of a 
suboptimal dose of 1 μg/ml soluble anti-mouse CD3. AntiFAP-mGITRL or antiFAP 
fusion protein was added at the indicated concentrations. CFSE dilution was assessed 
by flow cytometry on day 3 using a FACScan cytometer. All assays were performed at 
least twice in 6 replicates per sample. For analysis, the divison index of CFSE-positive 
cells was calculated with FlowJo. The division index is the average number of cell 
divisions of the total population, thereby including both dividing and non-dividing cells.  
Proliferation assays with C3H splenocytes were performed as described for BALB/c 
splenocytes with the exception of CD8+ T cells that were stimulated with 0.01 μg/ml 
soluble anti-mouse CD3 since this was determined as the dosis required for suboptimal 
TCR stimulation. Prior to FACS analysis, C3H samples were stained with anti-mouse 
CD4 APC or CD8a APC for clear identification of the different populations. All C3H 
proliferation assays were all performed three times in 2 to 6 replicates per sample. 
2.12.15 Suppression assays 
In suppression assays, BALB/c or C3H CD8+ T cells (1 x 105) were cocultured with 
different ratios of CD4+25+ cells (1:1, 3:1, 9:1) in the presence of 2 x 104 parental or 
mFAP transfected HEK 293 cells.  Splenocytes from BALB/c mice were stimulated with 
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2 x 104 mouse CD3/CD28 Dynabeads and cells from C3H mice were stimulated with 
0.1 μg/ml soluble anti-mouse CD3. AntiFAP-mGITRL or antiFAP fusion protein was 
added at different concentrations (0.01 – 10 μg/ml). CFSE dilution of CD8+ T cells was 
measured by flow cytometry after 3 days. C3H samples were co-stained with anti-
mouse CD8 APC before flow cytometric measurements. All assays were performed at 
least twice in triplicates. For analysis the average number of cell divisions (divison 
index) of CFSE-positive cells was calculated with FlowJo. The percent suppression 
was calculated by the equation ((1-(division index CD8+ & CD4+CD25+)/(division index 
CD8+)) x100. 
2.12.16 Measurement of cytokine production 
Cell culture supernatants from day 3 were analysed for IL-2 and IFN-γ levels by ELISA. 
The assays were performed using BD OptEIA Set Mouse IL-2 and BD OptEIA Set 
Mouse IFN-γ kits according to the manufacturer’s protocol.  
2.13 Animal experiments 
2.13.1 In vivo tumor growth 
Mice were inoculated subcutaneously in the flank with tumor cells resuspended in 100 
μl PBS. Tumor growth was monitored daily or every other day by caliper measurement 
and tumor volume was determined by (length x width2)/2. Body weight was monitored 
weekly. For therapy, mice were injected intravenously in the tail vein for five 
consecutive days with 100 μg fusion protein in 100 μl PBS-10% glycerol. The mice 
were euthanized when the tumor reached a diameter of 15 mm. All animal experiments 
were carried out under a project license granted by the Veterinäramt des Kantons 
Zürich (98/2008). 
2.13.2 Treatment protocol of CT26 tumors 
6 female BALB/c mice per group were inoculated s.c. with 1 x 105 CT26 cells. When 
diameter of the tumors reached 2 to 3 mm (between day 8 and 17), mice were treated 
with the fusion proteins on 5 consecutive days (PBS, mGITRL-Fc, antiCD33-mGITRL, 
antiFAP-mGITRL). For analysis of AH-1 specific CD8+ T cells, blood samples were 
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collected through tail vein puncture on day 3 after tumor inoculation and day 8 or 9 
after treatment start. 
2.13.3 Treatment protocol of LM8 tumors 
12 to 14 male C3H mice per group were inoculated s.c. with 2 x 106 LM8 cells. On day 
3, all mice showed palpable tumors of 1 to 2 mm in diameter. Mice received daily 
injections of fusion protein (PBS, antiFAP, antiCD33-mGITRL, antiFAP-mGITRL) from 
day 3 to 7. 
2.13.4 Preparation of single cell suspension from tumors 
In a separate experiment, a LM8 tumor of 5 mm in diameter was removed from one 
mouse and dissociated mechanically with a scalpel. A single cell suspension was 
obtained by enzymatic digestion in HBSS medium (Gibco/Invitrogen, Carlsbad, USA) 
containing 0.01% DNase I, 0.01% hyaluronidase, and 0.1% collagenase IA (all 
obtained from Sigma-Aldrich, St. Louis, USA). After 2 h incubation at 37 °C the 
suspension was filtered through a 70 μm cell strainer (BD Biosciences, San Jose, CA). 
2.13.5 Preparation of tumors for frozen sections 
LM8 tumors with 5 mm diameter were removed for histological analysis and 
immunostaining. Tumors were embedded in Tissue-Tek O.C.T. compound (Sakura 
Finetek, Zoeterwoude, Netherlands), frozen in liquid nitrogen and stored at -80 °C until 
sectioned.  
2.14 Statistical analysis 
Student’s unpaired t-test was used for statistical analysis of proliferation experiments. 
Log rank test was used for analysis of Kaplan-Meier survival curves.  
3 Results  41
3 Results 
3.1 Production of fusion proteins 
3.1.1 Cloning of the fusion proteins 
The fusion proteins containing the N-terminal antiFAP single chain antibody and murine 
or human GITRL at the C-terminus were constructed as shown schematically in Figure 
1. The recombinant antiFAP scFv antibody fragment was connected to the extracellular 
domain of murine GITRL (amino acids 43-173) by a 5 amino acid long GGGGS linker. 
The control constructs included antiFAP, antiFAP-hGITRL (amino acids 49 to 177 of 
human GITRL) and antiCD33-mGITRL. For purification and detection purposes, c-myc 
and hexahistidine tags were added at the C-terminal end. The amino acid sequences 
of the fusion proteins are provided in section 5. The mGITRL-Fc fusion protein, 
produced with HEK 293 mGITRL-Fc cells provided by H. Nishikawa, consists of the 
extracellular domain of mGITRL cloned at the N-terminus of a murine IgG2 Fc fragment 
including the hinge region.  
 
Figure 1. Schematic presentation of the fusion protein constructs. 
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3.1.2 Production and purification of fusion proteins 
For production of the fusion proteins, we generated stably transfected NS0 cell lines 
with the sequences for antiFAP-hGITRL, antiCD33-mGITRL, antiFAP-mGITRL and 
antiFAP. The resulting clones were analyzed for production of the fusion proteins by 
dot blot and the best producer for each fusion protein was expanded. The fusion 
proteins antiFAP-hGITRL, antiCD33-mGITRL, antiFAP-mGITRL and antiFAP were 
obtained from the supernatant of NS0 cells cultivated with the FibraStage system or in 
T300 cell culture flasks. Routine yields of fusion protein were 10 to 25 mg/l of cell 
culture supernatant, depending on clone productivity. The mGITRL-Fc fusion protein 
was purified from the supernatant of stably transfected HEK 293 cells cultivated in 
T300 cell culture flasks. The yield of the mGITRL-Fc fusion protein produced in the 
HEK 293 system was considerably lower than the yield of the other fusion proteins 
produced with the NS0 cells. The mGITRL-Fc transfected HEK 293 cells produced up 
to 0.5 mg/l fusion protein in T300 cell culture flasks.  
 
Figure 2. Visualization of the fusion proteins. The 5 fusion proteins were produced in stably 
transfected NS0 or HEK 293 cells and purified as described. Purified proteins were treated with 
reducing buffer, separated by SDS-PAGE and either visualized by Coomassie staining (A) or 
after transfer to nitrocellulose membrane by Western blot analysis with anti-His/anti-mouse (B), 
anti-mouse (C) or anti-bovine (D) antibody.  
The purity of each fusion protein was greater than 90% as determined by Coomassie-
stained reducing SDS-PAGE analysis (Figure 2A). The observed bands at a molecular 
weight of 50 kDa for the antiFAP-hGITRL, antiCD33-mGITRL, antiFAP-mGITRL and 
mGITRL-Fc fusion proteins correlate well with the calculated molecular mass of the 
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monomeric units of 45.2 kDa, 45.2 kDa, 45.8 kDa and 40.3 kDa respectively. The 
observed multiple bands of these fusion proteins were stained positively in Western 
blot (Figure 2B) and are possibly due to secondary modifications such as glycosylation 
of the GITRL domain (Hu et al., 2008; Wyzgol et al., 2009). Western blot detection of 
antiFAP-hGITRL with anti-His and anti-mouse/HRP revealed an additional band under 
37 kDa, indicating minor degradation of the fusion protein. The antiFAP single chain 
antibody was detected at the predicted molecular mass of 30 kDa.  
The mGITRL-Fc fusion protein does not contain a His-tag and was therefore purified 
with protein A beads recognizing the Fc domain. Since protein A beads also bind to 
bovine IgGs present in the FBS, an IgG removal step is required to obtain pure fusion 
protein after purification. Therefore, prior to cultivation of mGITRL-transfected HEK 293 
cells, we removed the bovine IgGs from the FBS with protein G beads that have a high 
affinity to bovine IgGs. The mGITRL-Fc fusion protein and bovine IgGs from the FBS 
have a similar molecular mass, therefore their bands in SDS-PAGE overlap. To check 
the purity of mGITRL-Fc fusion protein produced in medium with preabsorbed FBS, we 
performed a Western blot analysis with the purified protein. Our mGITRL-Fc fusion 
protein could be detected with anti-mouse antibody (Figure 2C). No bovine antibody 
was detected in the mGITRL-Fc band (Figure 2D), thereby confirming successful 
purification of the fusion protein without contaminating bovine IgGs.  
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3.2 Characterization of the fusion proteins 
3.2.1 Multimerization properties of the fusion proteins 
 
Figure 3. Analysis of multimerization of the fusion proteins by HPLC. The elution profile of the 
fusion proteins from a Superose 12 PC 3.2/30 column is displayed. The molecular weight of the 
3 main peaks was calculated (arrowheads). 
The multimerization state of the antiFAP-hGITRL, antiFAP-mGITRL and antiFAP fusion 
proteins was analyzed by size exclusion chromatography. Purified fusion protein 
samples were loaded on a Superose 12 PC 3.2/30 column and the molecular masses 
were calculated according to the retention time on the column (Figure 3). AntiFAP 
eluted in a main symmetric peak at a calculated molecular mass of 29 kDa 
corresponding to protein monomers and a small peak of homodimers at 67 kDa. 
AntiFAP-hGITRL eluted at a molecular weight of 53 kDa with a small shoulder at 120 
kDa corresponding to monomers with a small amount of trimers. AntiFAP-mGITRL 
shows an asymmetric peak with a maximum at 85 kDa indicating the dimeric assembly 
of antiFAP-mGITRL with only minor amounts of monomers. Thus, the three fusion 
proteins have different multimerization properties. 
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3.2.2 Binding of the fusion proteins to the corresponding receptors 
overexpressed on cell lines 
 
Figure 4. Binding analysis of the fusion proteins to their corresponding receptors on stably 
transfected cell lines. Purified fusion proteins were incubated with HEK 293 (column 1) parental 
(grey filled) or mFAP-transfected (black), CHO (column 2) parental (grey filled) or CD33-
transfected (black) and CMS5a (column 3) parental (grey filled), mGITR-transfected (dashed) or 
hGITR-transfected (black) cells and analyzed by flow cytometry. 
After biochemical characterization of the fusion proteins, we first verified their capacity 
to bind their cognate receptor by flow cytometry. For that purpose, cell lines 
overexpressing murine FAP, human CD33, murine GITR or human GITR  and parental 
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cell lines were stained with the fusion proteins. The antiFAP-hGITRL, antiFAP-mGITRL 
and antiFAP fusion proteins selectively bound to mFAP-expressing HEK 293 cells 
whereas, as expected, antiCD33-mGITRL and mGITRL-Fc did not recognize FAP 
(Figure 4, column 1). None of the fusion proteins bound to the parental HEK 293 cells. 
AntiCD33-mGITRL bound to CD33-transfected CHO cells whereas no binding was 
observed on parental CHO cells (Figure 4, column 2). All other fusion proteins showed 
no binding to any of the two CHO cell lines. The antiFAP single chain antibody did not 
bind to mGITR- or hGITR-transfected CMS5a cells (Figure 4, column 3). AntiFAP-
hGITRL, antiCD33-mGITRL, antiFAP-mGITRL and mGITRL-Fc all recognized the 
human and murine isoform of GITR. However, the human GITRL domain showed a 
stronger binding to human GITR than to murine GITR. Binding of mGITRL-Fc to 
mGITR-transfected CMS5a cells was better than to hGITR-transfected CMS5a cells. 
3.2.3 Binding of the fusion proteins to GITR on murine T lymphocytes 
We further analyzed binding of the fusion proteins to naturally GITR-expressing target 
cells. Splenocytes from BALB/c mice were isolated, stained with the fusion proteins 
and binding was measured by flow cytometry (Figure 5).  
The antiFAP-mGITRL, antiCD33-mGITRL and mGITRL-Fc fusion proteins all bound to 
murine GITR on both CD4+ and CD8+ T cell subsets. Geometric mean of fluorescence 
intensity (Gmean) after staining with antiFAP-mGITRL fusion protein was 151 on naïve 
CD4+ and 45 on CD8+T cells compared to 26 and 16, respectively, for the naïve cells 
stained with the detection system alone. Binding of antiCD33-mGITRL to naïve T cells 
resulted in Gmean values of 162 and 46 for CD4+ and CD8+ T cells, respectively.  
Thus, our fusion proteins were able to detect the higher GITR expression on naïve 
CD4+ T cells than on naïve CD8+ T cells (Kanamaru et al., 2004).  
Naïve CD4+ T cells, but not naïve CD8+ T cells, stained with the mGITRL-containing 
constructs showed an asymmetric peak. This is possibly due to the CD4+25+ Treg cells 
within the CD4+ population since Treg cells constitutively express high levels of GITR 
(Kanamaru et al., 2004; McHugh et al., 2002; Nocentini et al., 1997). 
Activated CD8+ and CD4+ T cells show maximal GITR expression 48h after stimulation 
(Ronchetti et al., 2004; Suvas et al., 2005). We, therefore, stimulated BALB/c 
splenocytes with anti-CD3/CD28 microbeads for 48h and then analyzed the binding of 
our fusion proteins to GITR. The antiFAP-mGITRL, antiCD33-mGITRL and mGITRL-Fc 
fusion proteins all showed enhanced binding to activated T cells compared to naïve T 
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cells. Binding of these fusion proteins to activated CD4+ T cells increased 2.3-fold 
compared to naïve CD4+ T cells. The Gmean of antiFAP-mGITRL was 345 for 
activated CD4+ T cells compared to 151 for naïve cells. Gmean values of 360 and 162 
for antiCD33-mGITRL and 1154 and 495 for mGITRL-Fc were measured for activated 
and naïve CD4+ T cells, respectively. The binding of the fusion proteins to activated 
CD8+ T cells increased nearly 4-fold, as shown by the Gmean values on activated 
CD8+ T cells of 186 for antiFAP-mGITRL, 179 for antiCD33-mGITRL and 675 for 
mGITRL-Fc compared to 45, 46, and 183, respectively, for naïve CD8+ T cells.  
AntiFAP and antiFAP-hGITRL did not bind to mGITR on either naïve or activated T 
cells. In contrast to the staining with mGITR-transfected CMS5a cells, the antiFAP-
hGITRL did not show any crossreactivity with the naturally mGITR-expressing cells.  
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Figure 5. Binding analysis of the fusion proteins to primary murine splenocytes. Fresh BALB/c 
splenocytes were activated for 48h with anti-CD3/CD28 microbeads, stained with the purified 
fusion proteins and analyzed by flow cytometry. Columns 1 and 2 show naïve (black) and 
stimulated (dashed) CD4+ and CD8+ gated T lymphocytes, respectively. As control (ctrl), naïve 
T cells stained with the detection system alone are shown (filled grey). 
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3.2.4 Comparison of binding affinities to murine FAP 
We previously showed that the antiFAP-hGITRL, antiFAP-mGITRL and antiFAP fusion 
proteins specifically recognize mFAP on stably transfected cells (Figure 4), thereby 
confirming that the antiFAP domain of the fusion proteins is functional. In a next step, 
we quantified the binding of the scFv to murine FAP. The apparent affinities (KDapp) of 
the constructs were measured on mFAP-transfected HEK 293 cells by analyzing the 
binding of serial dilutions of the fusion proteins (Figure 6). Half maximum fluorescence 
intensity was used to calculate the apparent affinity to murine FAP. For all fusion 
proteins, KDapp values in the low nanomolar range were determined. AntiFAP-hGITRL 
and antiFAP showed KDapp values to mFAP of 35 ± 21 nM and 29 ± 11 nM, 
respectively, thus displaying no significant differences in binding affinities. However, 
antiFAP-mGITRL showed a better apparent affinity of 4.5 ± 3.1 nM. 
 
 
Figure 6. Determination of the apparent affinity of the fusion proteins to murine FAP. mFAP-
transfected HEK 293 cells were incubated with serial dilutions of fusion protein (circle: antiFAP-
hGITRL, cross: antiFAP-mGITRL, triangle: antiFAP) and stained for flow cytometry analysis. 
Mean fluorescence intensity of live cells was converted to percentage of maximal binding and 
plotted against fusion protein concentration. Apparent affinity is calculated from half maximum 
binding. One representative experiment of three is shown. 
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3.2.5 GITR binding analysis by surface plasmon resonance 
We next compared the binding affinities of the fusion proteins to recombinant murine 
GITR. This interaction was assessed by surface plasmon resonance (SPR) on a CMS5 
chip coated with recombinant murine GITR-Fc protein (Figure 7). The KD values were 
calculated by fitting of the 1:1 Langmuir binding model to the steady-state plateaus 
reached after injection of the fusion proteins. The antiFAP-mGITRL fusion protein 
bound mGITR with a KD of 1190 ± 242 nM, antiCD33-mGITRL bound with a KD of 
1710 ± 105 nM and mGITRL-Fc bound with a KD of 1790 ± 136 nM. AntiFAP-hGITRL, 
antiFAP and hGITRL-Fc did not bind to murine GITR.  
To compare the affinities of the human and murine GITR/GITRL systems, we also 
measured the binding to recombinant human GITR (Figure 8). The KD values were 
calculated by fitting of the double-referenced association and dissociation data by a 
simple 1:1 interaction model. AntiFAP-hGITRL bound to hGITR with a KD of 14 ± 2 nM 
and hGITRL-Fc bound with a KD of 10 ± 2 nM. AntiFAP-mGITRL, antiFAP and 
mGITRL-Fc fusion proteins did not bind to human GITR.  
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Figure 7. Surface plasmon resonance analysis of the binding to immobilized murine GITR. 
Sensograms of injections of serial dilutions of antiFAP-mGITRL (A, inset), antiCD33-mGITRL 
(B, inset), mGITRL-Fc (C, inset), antiFAP-hGITRL (D), antiFAP (E) and hGITRL-Fc (F) are 
shown. The outer graph from A, B, C shows the nonlinear 1:1 Langmuir fitting of the steady-
state binding data. 
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Figure 8. Surface plasmon resonance analysis of the binding to immobilized human GITR. 
Sensograms of injections of serial dilutions of antiFAP-hGITRL (A), hGITRL-Fc (B), antiFAP-
mGITRL (C), antiFAP (D) and mGITRL-Fc (E) are shown. 
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3.3 Targeting the tumor stroma 
3.3.1 Purification of T cell subsets 
To analyze the costimulatory effect of the fusion proteins on different murine T cell 
subsets, we separated regulatory and effector T cells using MACS microbeads. 
Positive selection with anti-mouse CD8 microbeads typically resulted in a 95% pure 
CD8+ population (Figure 9A). The CD4+25+ Regulatory T Cell Isolation Kit routinely 
yielded a 90% pure CD4+25- population and an 85-95% pure CD4+25+ population as 
determined by flow cytometry (Figure 9B, C). 
 
Figure 9. Purified T cell subsets. Freshly isolated BALB/c splenocytes were separated into CD8+ 
(A), CD4+25- (B) and CD4+25+ (C) T cell subsets using MACS microbeads. Purity of the 
populations was controlled by flow cytometry analysis. The dotplots (right column) show the 
phenotype of the live population gated in the forward/side scatter dotplot (left column). Numbers 
in the dotplots refer to the percentage of cells within the respective gate. 
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3.3.2 Costimulation of CD4+ T cells 
The costimulatory activity of the fusion proteins on murine CD4+25- T cells was 
assessed by measuring the proliferation upon TCR stimulation with 1 μg/ml soluble 
anti-CD3 antibody. This suboptimal TCR stimulus allowed to monitor the costimulatory 
effect of GITR activation since the costimulatory effect would be less pronounced at 
higher anti-CD3 concentrations. Proliferation of CD4+ T cells was analyzed after 3 days 
and the average number of divisions of the total T cell population (division index) was 
calculated with FlowJo as described (Figure 10A). The resulting division index of lower 
than 1 is due to the fact that a suboptimal TCR stimulus was used and that not all cells 
within the T cell population responded to this weak stimulus. We further added fusion 
protein and FAP-negative or FAP-positive HEK 293 cells to the T cell culture to assess 
the influence of costimulation on the T cells. Addition of 1 µg/ml soluble antiFAP-
mGITRL to CD4+25- cells led to the same proliferative activity as with the antiFAP 
control construct. However, presentation of antiFAP-mGITRL in a membrane-bound 
form (1 µg/ml antiFAP-mGITRL with mFAP-transfected HEK 293 cells) increased 
proliferation of CD4+25- T cells by 43%. In contrast to the lower concentration, 10 µg/ml 
of antiFAP-mGITRL in the presence of HEK 293 parental cells led to a 39% increase in 
T cell proliferation compared to cultivation in the presence of antiFAP. Presentation of 
10 µg/ml antiFAP-mGITRL by FAP-positive HEK 239 cells did not further increase 
proliferation compared to fusion protein in the presence of parental HEK 293 cells. It is 
of note that the proliferation of CD4+ T cells was equal for FAP-presented antiFAP-
mGITRL at both concentrations tested. This indicates that in a setting where the fusion 
protein is being presented to the T cells by mFAP transfected HEK 293 cells, lower 
fusion protein concentrations are sufficient to efficiently costimulate CD4+ T cells.  
The activation and function of CD4+25- cells was assessed by measuring cytokine 
secretion. IFN-γ and IL-2 in the supernatant from the proliferation assay was quantified 
by ELISA. Parental or mFAP-transfected HEK 293 cells cultivated alone produced no 
IL-2 or IFN-γ (data not shown). Secretion of IFN-γ by CD4+ T cells was not enhanced 
by costimulation with any concentration of unbound antiFAP-mGITRL in the presence 
of HEK 293 parental cells compared to cultivation in the presence of antiFAP (Figure 
10B). However, presentation of antiFAP-mGITRL by mFAP expressing cells increased 
IFN-γ production to 1952 pg/ml compared to 639 pg/ml for cultivation with antiFAP (at 1 
µg/ml). The same 3-fold increase was also observed at 10 µg/ml fusion protein. Thus a 
substantial increase in IFN-γ production could not be triggered through antiFAP-
mGITRL in the presence of parental HEK 293 cells at the tested concentrations. In 
contrast, secretion of IL-2 was enhanced by soluble fusion protein (Figure 10C). 
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Unbound antiFAP-mGITRL in the presence of parental HEK 293 cells increased IL-2 
production 2.3-fold at 1 μg/ml and 2.7-fold at 10 μg/ml compared to control cultivation 
in the presence of antiFAP. Presence of HEK 293 mFAP cells instead of parental cells 
led to a 2.9-fold increase at 1 μg/ml and a 3.2-fold increase at 10 μg/ml compared to 
cultivation with antiFAP. Thus, the presence of HEK 293 mFAP cells further enhanced 
IL-2 production by CD4+ T cells even at low fusion protein concentrations.  
 
Figure 10. antiFAP-mGITRL presented by FAP-positive cells enhances proliferation of CD4+ T 
cells. 1 x 105 freshly isolated BALB/c CD4+25- T cells were stimulated with 1 μg/ml soluble anti-
CD3 antibody and various concentrations of antiFAP-mGITRL or control construct. 2 x 104 
mFAP-positive (HEK 293 mFAP) or parental cells (HEK 293 PA) were added for presentation of 
the fusion protein. Proliferation of T cells was assessed by measuring CFSE-dilution on day 3 
and calculating the average number of cell divisions (division index) with FlowJo (A). IFN-γ (B) 
and IL-2 (C) production was quantified by ELISA. *:p<0.05, **:p<0.01, ***:p<0.001 
3.3.3 Costimulation of CD8+ T cells 
The influence of FAP targeting on the activation of CD8+ T cells was analyzed by 
proliferation assays. Proliferation of CD8+ T cells was measured in the presence of a 
suboptimal dosis of 1 µg/ml soluble anti-CD3 antibody and the fusion proteins (Figure 
11A). Presentation of antiFAP-mGITRL by HEK 293 mFAP cells enhanced proliferation 
of CD8+ T cells compared to antiFAP-mGITRL with parental HEK 293 cells or 
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compared to antiFAP control construct, as the division indexes were 0.37, 0.20 and 
0.11, respectively (at 1 µg/ml fusion protein). In contrast to CD4+ T cells, CD8+ T cells 
produced minimal amounts of IFN-γ upon stimulation with soluble anti-CD3 (Figure 
11B). Unbound antiFAP-mGITRL as costimulatory signal triggered significant IFN-γ 
secretion in the presence of HEK 293 parental cells. Moreover, the presence of HEK 
293 mFAP cells led to a further 3.8-fold increase of IFN-γ concentration in the 
supernatant at 1 μg/ml antiFAP-mGITRL compared to unbound fusion protein. At 10 
μg/ml antiFAP-mGITRL, the increase was 2.6-fold compared to cultivation in the 
presence of parental HEK 293 mFAP cells. Maximal IFN-γ secretion reached 
comparable levels at both 1 and 10 µg/ml of targeted fusion protein. Overall 
costimulatory effect on proliferation of CD8+ T cells was stronger than on CD4+ T cells. 
 
Figure 11. antiFAP-mGITRL presented by FAP-positive cells costimulates CD8+ T cells. 1 x 105 
purified BALB/c CD8+ T cells were incubated with 1 μg/ml soluble anti-CD3 antibody, various 
concentrations of antiFAP-mGITRL or control construct and HEK 293 mFAP or HEK 293 PA 
cells (2 x 104). Costimulatory effect of the fusion protein was measured by CFSE-dilution (A) 
and IFN-γ production (B) on day 3. **:p<0.01, ***:p<0.001 
3.3.4 Inhibition of Treg-mediated suppression 
GITRL has not only been described to costimulate CD8+ and CD4+ effector T cells, but 
also to reduce the inhibitory effect of Treg cells on effector T cells. We therefore 
cocultivated CD4+25+ Treg cells with CD8+ effector T cells at a ratio of 1:1 in the 
presence of mFAP-expressing or parental HEK 293 cells and varying concentrations of 
fusion protein to measure the influence of antiFAP-mGITRL on Treg-mediated 
suppression (Figure 12). Since the overall stimulation by soluble antiCD3 antibody was 
quite weak, the suppression assays were performed with anti-CD3/CD28 beads that 
allowed good monitoring of the suppressive capacity of Treg cells. Basal suppression 
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by Treg cells was 62% and, as expected, antiFAP control construct did not reverse 
suppressive Treg cell activity (Figure 12, black bars). Soluble antiFAP-mGITRL in the 
presence of parental HEK 293 cells, showed a dose-dependent effect on reduction of 
suppressive activity of Treg cells (Figure 12, light grey bars). Indeed, 0.01 µg/ml of 
soluble antiFAP-mGITRL in the presence of parental HEK 293 cells did not alleviate 
suppression but at 0.1 µg/ml suppression of CD8+ T cells was reduced to 48%. At 1 
µg/ml antiFAP-mGITRL, inhibition of suppression nearly reached its maximum. 
Inhibition of suppression was strongly enhanced by antiFAP-mGITRL in the presence 
of mFAP HEK 293 cells (Figure 12, dark grey bars). 0.01 µg/ml antiFAP-mGITRL 
presented by HEK 293 mFAP cells already reduced suppression to 42%. Suppression 
could be lowered up to 32% but not completely abrogated at higher fusion protein 
concentrations. 0.01 µg/ml antiFAP-mGITRL presented by FAP-positive cells was 
nearly as effective in overcoming Treg-mediated suppression as the 100-fold higher 
dose of 1 µg/ml unbound antiFAP-mGITRL (42% to 38%, p=0.039).  
 
Figure 12. antiFAP-mGITRL reduces suppression by Treg cells in a dose-dependent manner. 1 
x 105 BALB/c CD8+ T cells were cocultivated with 1 x 105 CD4+25+ Treg cells in the presence of 
2 x 104 anti-CD3/CD28 microbeads and antiFAP-mGITRL or antiFAP for 3 days. HEK 293 
mFAP or parental cells were added for presentation of the fusion protein. In a dose-response 
assay, different concentrations of fusion protein were used and proliferation of Teff cells was 
measured by CFSE-dilution. *:p<0.05, ***:p<0.001 
The influence of Treg:Teff ratio on suppressive activity was tested at 0.1 and 1 µg/ml of 
fusion protein (Figure 13). Without GITRL stimulus, at a 1:1 Treg:Teff ratio Treg cells 
suppressed the proliferation of CD8+ T cells by 77% (p<0.0001), 35% at a 1:3 ratio 
(p=0.003) and 14% at a 1:9 ratio (Figure 13A). At 0.1 μg/ml, antiFAP-mGITRL was 
potent in relieving suppression by Treg cells, thereby being significantly more effective 
in the presence of mFAP HEK 293 cells than parental HEK 293 cells (Figure 13A, dark 
grey vs. light grey bars). At a 1:3 ratio, antiFAP-mGITRL in the presence of parental 
HEK 293 cells partially inhibited the suppressive effect whereas the fusion protein 
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presented by mFAP HEK 293 cells could completely restore CD8+ Teff cell proliferation 
compared to unsuppressed CD8+ T cells (p=0.236). 1 μg/ml antiFAP-mGITRL restored 
proliferation to the same extent for both bound and unbound fusion protein at all 
Treg:Teff ratios (Figure 13C, dark grey vs. light grey bars). Similar effects were seen in 
the secretion of IFN-γ by CD8+ T cells (Figure 13B, D). 0.1 μg/ml antiFAP-mGITRL in 
the presence of parental HEK 293 cells could increase IFN-γ production of CD8+ T 
cells compared to cells cultivated with antiFAP (Figure 13B, light grey vs. black bars). 
This effect was enhanced by the use of FAP-positive cells. At a 1:9 Teff:Treg ratio, 
where inhibition of proliferation and IFN-γ secretion was only minor, the presence of 
mFAP HEK 293 cells with antiFAP-mGITRL increased IFN-γ secretion by CD8+ T cells 
to levels even above the usual production seen for anti-CD3/CD28 stimulated non 
suppressed CD8+ T cells. Stimulation of Treg:Teff cocultures with 1 μg/ml antiFAP-
mGITRL partially restored IFN-γ production but no difference could be observed 
between bound and unbound fusion protein (Figure 13D).  
 
Figure 13. antiFAP-mGITRL presented by FAP-positive cells reduces suppression by BALB/c 
Treg cells. 1 x 105 BALB/c CD8+ T cells were cocultivated with various ratios of CD4+25+ Treg 
cells in the presence of 2 x 104 anti-CD3/CD28 microbeads and antiFAP-mGITRL or antiFAP for 
3 days. HEK 293 mFAP or parental cells were added for presentation of the fusion protein. 
Treg:Teff ratios were titrated at 0.1 μg/ml (A, B) and 1 μg/ml (C, D) fusion protein and 
proliferation (A, C) and IFN-γ production (B, D) was measured. *:p<0.05. 
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3.3.5 Therapy of CT26 tumors 
Since antiFAP-mGITRL showed significant costimulatory properties in vitro, we further 
tested the fusion proteins in a murine cancer model. We first investigated if the fusion 
proteins influence the growth of a stroma-inducing tumor. BALB/c mice were inoculated 
with the syngeneic colorectal carcinoma line CT26. This tumor line has been reported 
to induce FAP-positive stroma (Loeffler et al., 2006; Santos et al., 2009). Preliminary 
experiments showed that tumor growth was heterogeneous, therefore the treatment 
start with the fusion proteins was adapted individually to each mouse to the time when 
the tumors had reached 2 to 3 mm in diameter. Five daily doses of 100 μg fusion 
protein were injected i.v. in the tail vein and tumor growth was monitored for 60 days. 
Treatment with antiFAP-mGITRL, antiCD33-mGITRL or control PBS resulted in similar 
tumor progression whereas administration of mGITRL-Fc fusion protein significantly 
delayed tumor growth (Figure 14A, p=0.0476 compared to PBS group). One mouse of 
the mGITRL-Fc group completely rejected the tumor and remained tumor-free until the 
end of the experiment when it was euthanized. To follow the tumor-specific T cell 
response in the mice, we measured the MHC class I-restricted peptide-specific 
cytotoxic T lymphocyte response toward the AH-1 peptide. Immunization of mice with 
CT26 cells had revealed the existence of an immunodominant H-2Ld-restricted, gp70-
derived epitope termed AH-1 (Huang et al., 1996). On day 3 after tumor inoculation, 
blood lymphocytes were stained with H-2Ld/AH-1138-147 tetramer. The tumor-bearing 
mice had no AH-1 specific CD8+ T cells compared to naïve mice (Figure 14B). 
Tetramer staining of blood lymphocytes 8 or 9 days after therapy start showed no 
significant increase in AH-1 specific cells among CD8+ T cells for the groups treated 
with antiFAP-mGITRL, antiCD33-mGITRL and PBS (Figure 14C-E). However, 
mGITRL-Fc treated mice had increased numbers of AH-1 specific T cells in the blood. 
Four mice still had low numbers of specific T cells whereas in two mice a dramatic 
increase was observed (3% and 6% of CD8+ T cells). The mouse showing 6% AH-1+ of 
CD8+ T cells on day 8 after beginning of treatment (Figure 14F) showed tumor 
regression and was tumor-free 16 days after start of treatment with 13% AH-1 specific 
CTLs (Figure 14G). 
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Figure 14. mGITRL-Fc delays growth of CT26 tumors. BALB/c mice (n=6 per group) were 
injected s.c. in the left flank with 1 x 105 CT26 tumor cells and tumor progression was 
monitored. When tumors had reached 2-3 mm in diameter, mice were treated daily with i.v. 
injections of 100 µg fusion protein on 5 consecutive days (A, arrows). Kaplan-Meier survival 
curves of the treated and control groups are shown (A). For detection of a CD8 response 
against H-2Ld-restricted AH-1 epitope, blood samples from day 3 after tumor inoculation (B) and 
day 8 or 9 after treatment start (C) were taken from the tail vein and stained with for CD8 and 
with AH-1 tetramer. Naïve mice without a tumor are shown as control. Percentage of tetramer-
positive cells for each mouse and mean of each group are represented in the graphs.  
Representative AH-1 tetramer staining on day 8 or 9 is shown for antiFAP (D), antiFAP-mGITRL 
(E) and mGITRL-Fc (F). Tetramer staining of T cells from mouse shown in F was performed 
again on day 16 (G). *: p<0.05 as determined by log-rank analysis between mGITRL-Fc and 
PBS group. 
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3.4 Targeting of sarcomas 
3.4.1 Costimulation of T cells 
We further wanted to test if the fusion proteins influence the growth of a FAP+ tumor. 
The murine osteosarcoma cell line LM8 is FAP+ but is syngeneic to C3H mice and not 
BALB/c mice. Therefore, we first assessed the influence of the fusion proteins on 
purified T cell populations from that mouse strain. Isolation of T cell subsets from C3H 
splenocytes was performed as for BALB/c mice and yielded the same range of purity. 
Splenocytes of C3H mice show similar GITR expression pattern than BALB/c mice both 
before and after in vitro activation (Shimizu et al., 2002).  
 
 
Figure 15. antiFAP-mGITRL presented by FAP-positive cells enhances production of IL-2 and 
IFN-γ by CD4+ T cells. 1 x 105 freshly isolated C3H CD4+25- T cells were stimulated with 1 μg/ml 
soluble anti-CD3 antibody and various concentrations of antiFAP-mGITRL or control construct. 
2 x 104 mFAP-positive (HEK 293 mFAP) or parental cells (HEK 293 PA) were added for 
presentation of the fusion protein. After 3 days, IL-2 (A) and IFN-γ (B) production was quantified 
by ELISA from the supernatant of the culture. **:p<0.01, ***:p<0.001 
The costimulatory activity of the fusion protein on C3H CD4+25- T cells was analyzed 
by measuring proliferation, IL-2 production and secretion of IFN-γ upon suboptimal 
TCR stimulation with 1 μg/ml soluble anti-CD3 antibody. Monitoring of CFSE staining in 
CD4+25- cells after 3 days revealed a main peak of undivided T cells together with very 
few divided cells for all tested concentrations of fusion protein (data not shown). 
Proliferation of CD4+ T cells was very low but production of cytokines by CD4+ T cells 
could be induced in our system. Secretion of IL-2 was enhanced 4-fold upon 
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costimulation with unbound or FAP-presented antiFAP-mGITRL compared to anti-CD3 
stimulus alone (Figure 15A, p<0.0001). Production of IFN-γ was also enhanced upon 
stimulation with antiFAP-mGITRL in the presence of parental HEK 293 cells but could 
not be further increased by using the mFAP HEK 293 cells (Figure 15B). In both cases, 
increased cytokine production was only dependent on presence of antiFAP-mGITRL 
construct but it was neither dose-dependent at the tested concentrations nor was it 
influenced by presentation by FAP-positive cells.  
 
Figure 16. antiFAP-mGITRL presented by FAP-positive cells costimulates CD8+ T cells. 1 x 105 
purified C3H CD8+ T cells were incubated with 0.01 μg/ml soluble anti-CD3 antibody, various 
concentrations of antiFAP-mGITRL or control construct and 2 x 104 HEK 293 mFAP or HEK 293 
PA cells. Costimulatory effect of the fusion protein was measured by CFSE-dilution (A) and IFN-
γ production (B) on day 3. *:p<0.05, ***:p<0.001 
The costimulatory properties of antiFAP-mGITRL on CD8+ T cells were further 
determined by measuring proliferation and IFN-γ production after exposure to 
suboptimal TCR and fusion protein stimulation. Proliferation of CD8+ T cells was 
enhanced by soluble antiFAP-mGITRL in a concentration-dependent manner as shown 
by the proliferation indexes of 0.33 at 0.1 μg/ml and 0.51 at 1 μg/ml (p<0.0001, Figure 
16A). Presentation of the fusion protein by FAP-positive cells led to further increase in 
proliferation but maximal proliferation was not dose-dependent. Although CD8+ T cells 
proliferated upon TCR stimulation, no IFN-γ secretion was detected (Figure 16B). 
Costimulation with soluble antiFAP-mGITRL in the presence of parental HEK 293 cells 
triggered IFN-γ production in a dose-dependant fashion. Stimulation in the presence of 
mFAP HEK 293 cells further increased secretion at 0.1 μg/ml antiFAP-mGITRL. At 1 
μg/ml antiFAP-mGITRL, IFN-γ levels were comparable after stimulation in the presence 
of mFAP HEK 293 cells or parental HEK 293 cells.  
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3.4.2 Inhibition of Treg-mediated suppression 
 
Figure 17. antiFAP-mGITRL presented by FAP-positive cells reduces suppression by C3H Treg 
cells. 1 x 105 C3H CD8+ T cells were cocultivated with CD4+25+ Treg cells in the presence of 0.1 
μg/ml soluble anti-CD3 antibody and antiFAP-mGITRL or antiFAP for 3 days. HEK 293 mFAP 
or parental cells were added for presentation of the fusion protein. In a dose-response assay, 
Treg and Teff cells were cultivated at a 1:1 ratio at different concentrations of fusion protein and 
proliferation of Teff cells was measured by CFSE-dilution (A). Secretion of IFN-γ was quantified 
in the supernatant by ELISA (B). *:p<0.05 
To determine if antiFAP-mGITRL could also abrogate Treg-mediated suppression of 
C3H T cells, we performed cocultivation assays with CD8+ T cells and CD4+25+ Treg 
cells at a 1:1 ratio. Stimulation with a suboptimal dose of anti-CD3 antibody (0.01 
μg/ml) lead to weak proliferation of the CD8+ T cells, therefore we used a dose of 0.1 
μg/ml anti-CD3 for the suppression assays which allowed to better monitor the effect of 
the regulatory T cells. For TCR-stimulated CD8+ T cells we calculated a division index 
of 0.87 (Figure 17A). This was lowered to 0.44 in the presence of Treg cells 
(p=0.0019), thus resulting in a standard suppression of proliferation of 50%. Addition of 
soluble antiFAP-mGITRL to the coculture inhibited Treg-mediated suppression in a 
dose-dependent manner. At 10 μg/ml soluble fusion protein in the presence of parental 
HEK 293, proliferation of CD8+ T cells was completely restored (division index of 0.84). 
Presentation of FAP-presented antiFAP-mGITRL to the coculture already cancelled out 
the effect of Treg cells at 0.1 μg/ml fusion protein (division index of 0.86). The 
supernatant from these coculture assays were analyzed by ELISA to quantify IFN-γ 
secretion by CD8+ T cells. Parental or mFAP-transfected HEK 293 cells as well as Treg 
cells alone did not produce IFN-γ (data not shown). TCR stimulation of CD8+ T cells 
induced very strong IFN-γ secretion of 9217 pg/ml that was almost completely 
abolished in the presence Treg cells where 50 to 215 pg/ml were detected (Figure 
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17B). Both, soluble and membrane-bound antiFAP-mGITRL increased IFN-γ 
production in a dose-dependent manner, with FAP-presented antiFAP-mGITRL always 
being more efficient. However, the overall rescue of IFN-γ secretion was very low with 
FAP-presented antiFAP-mGITRL where a maximum of 1490 pg/ml could be reached, 
corresponding to 16% of the unsuppressed amount.  
3.4.3 Characterization of the sarcoma LM8 
 
Figure 18. LM8 cells from cell culture and from tumor suspension are FAP-positive. LM8 cells 
cultivated in T-flasks were analyzed for FAP expression by flow cytometry using ESC11 antiFAP 
antibody (A) and the fusion proteins (C). LM8 tumor of 5 mm diameter was enzymatically 
digested and the single cell suspension was stained with ESC11 antiFAP antibody (B) and the 
fusion proteins (D). Samples were stained with antiFAP-mGITRL (blue), antiCD33-mGITRL 
(orange), antiFAP (green), antiFAP-hGITRL (purple) and isotype control/secondary antibody 
(grey area). 
Since FAP expression on osteosarcoma cells has been reported (Dolznig et al., 2005), 
we measured FAP expression on LM8 osteosarcoma cells. This highly aggressive 
osteosarcoma cell line is a subclone from Dunn osteosarcoma and has high metastatic 
potential to the lung (Asai et al., 1998). It had been obtained by 8 rounds of i.v. 
injections of Dunn cells into C3H mice, isolation of pulmonary metastasis and 
reinjection of these cells into naïve mice. We first assessed the FAP status of the LM8 
cell line by staining with our fusion proteins and the anti-FAP antibody ESC11. The 
ESC11 antibody detected FAP on LM8 cells and the isotype control remained negative 
(Figure 18B). Binding of antiFAP, antiFAP-mGITRL and antiFAP-hGITRL to LM8 cells 
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confirmed the expression of FAP on this tumor cell line (Figure 18A). The antiCD33-
mGITRL fusion protein did not bind. Parental Dunn cells were subjected to the same 
staining and showed very weak FAP expression, thereby revealing the different 
phenotype of these two cell lines (data not shown). To analyze whether LM8 cells 
maintain expression of FAP in the tumor microenvironment, we removed a s.c. LM8 
tumor from one mouse. After enzymatic digestion, the single cell suspension was 
subjected to staining for FAP and measured by flow cytometry. The dissociated cells 
stained positively with antiFAP, antiFAP-mGITRL, antiFAP-hGITRL (Figure 18C) and 
ESC11 (Figure 18D). No binding was detected with antiCD33-mGITRL or isotype 
control. Furthermore, immunohistochemical analysis of frozen sections of LM8 tumors 
confirmed the expression of FAP on tumor cells, as determined by positive staining 
with ESC11 and ESC14 anti-FAP antibodies (Figure 19C-F). H&E staining of the LM8 
tumor section revealed densely packed tumor cells (Figure 19A, B).  
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Figure 19. Detection of FAP on frozen sections of LM8 tumors. Immunohistochemical 
microscopy of 6 µm thick sections of LM8 tumors 5 mm in diameter stained with H&E (A, B), 
ESC11 (C, D), ESC14 (E, F) and isotype control (G, H) is shown. Tumor sections were 
analyzed with a Polyvar 2 microscope with 10x (A, C, E, G) and 40x (B, D, F, H) magnification 
objectives.  
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3.4.4 Therapy of LM8 tumors 
After having identified a FAP+ sarcoma cell line, we tested the potency of the fusion 
proteins to inhibit growth of the corresponding FAP-expressing tumor in a syngeneic 
mouse model. We injected 2 x 106 LM8 cells s.c. into the right flank of C3H mice. On 
day 3 when treatment was started, all mice had developed tumors with 2 to 3 mm in 
diameter. Fusion protein was administered on 5 consecutive days and tumor growth 
was monitored. Animals treated with antiCD33-mGITRL, antiFAP and PBS exhibited 
similar tumor progression and survival (Figure 20). Mice treated with antiFAP-mGITRL 
showed delayed tumor growth and enhanced survival in comparison to the other group. 
However, this effect was not statistically significant as determined by log-rank test 
between antiFAP-mGITRL and PBS treated groups (p=0.0606).  
 
Figure 20. antiFAP-mGITRL slightly delays tumor growth of LM8 osteosarcoma. C3H mice were 
injected s.c. in the right flank with 2 x 106 LM8 tumor cells. Mice received daily i.v. injections of 
100 µg fusion protein from day 3 to 7 (marked by arrows, n=12-14 mice per group). Kaplan-
Meier survival curve of the different therapy groups is shown.  
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4 Discussion 
The here presented antiFAP-mGITRL bispecific fusion protein aims at modulating the T 
cell response in the tumor microenvironment. We show that FAP-specific crosslinking 
of GITR is significantly more efficient in costimulating T cells and overcoming Treg-
mediated suppression than untargeted GITR stimulation. Therefore, the use of 
antiFAP-mGITRL is very attractive for immunotherapeutic applications where a site-
specific immune response is to be induced while avoiding systemic toxicity. 
Among the TNF receptor superfamily members available as costimulatory receptors, 
GITR has the valuable characteristic to be expressed not only on activated but also on 
naïve T cells (Kanamaru et al., 2004; McHugh et al., 2002; Nocentini et al., 1997). 
Costimulation of T cells through triggering of GITR with its natural ligand or agonistic 
antibodies has been shown to stimulate antiviral (Dittmer et al., 2004), antiparasitic 
(Haque et al., 2010) and antitumoral responses (Calmels et al., 2005; Cho et al., 2009; 
Cohen et al., 2006; Hu et al., 2008; Ko et al., 2005; Liu et al., 2009; Nishikawa et al., 
2008; Nishioka et al., 2008; Piao et al., 2009; Zhou et al., 2007). Soluble mGITRL 
abrogates Treg-mediated suppression (Ji et al., 2004) and tumor growth can be 
delayed through therapy with Fc-mGITRL fusion protein (Hu et al., 2008), immunization 
with plasmids encoding a tumor rejection antigen and mGITRL (Nishikawa et al., 2008) 
or tumor cells transfected with mGITRL (Calmels et al., 2005; Cho et al., 2009; Piao et 
al., 2009). To improve the therapeutic efficacy and biochemical properties of mGITRL, 
we added the FAP-targeting component to recombinant mGITRL.  
The molecular weight of a fusion protein is of major importance for serum half-life of the 
construct. Small antibody constructs rapidly undergo systemic clearance through renal 
excretion as their molecular weight is below the renal retention limit of ~55 kDa. 
Through increasing the molecular weight of the construct, in vivo half-life can be 
extended by avoiding rapid kidney elimination. Like most TNF receptor superfamily 
(TNFRSF) ligands that have been described as trimers (Bossen et al., 2006), human 
GITRL shows loose trimeric assembly in dynamic equilibrium with either monomers 
(Chattopadhyay et al., 2007) or dimers (Zhou et al., 2008). N-terminal fusion of antiFAP 
scFv to hGITRL did impact on the hGITRL ectodomain by hampering trimer formation 
which, in turn, resulted in predominant monomeric antiFAP-hGITRL. In contrast, crystal 
structure as well as ultracentrifugation and gelfiltration data have shown dimer 
formation of mGITRL at 40 µM (Chattopadhyay et al., 2008) and a concentration-
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dependent equilibrium of monomers and dimers below 10 µM (Zhou et al., 2008). Like 
mGITRL, our antiFAP-mGITRL fusion protein consists of dimers and low amounts of 
monomer at 4.4 µM. Thus, the N-terminal fusion of antiFAP scFv to mGITRL did not 
impair dimerization of the fusion protein. Our dimeric antiFAP-mGITRL fusion protein 
displayed a molecular weight of 85 kDa, thereby corresponding approximately to the 
size of a minibody (80 kDa) and being above the threshold of renal excretion. 
Comparative biodistribution studies have shown that this minibodies display better 
tumor penetration and in vivo half-life than smaller scFvs or diabodies and faster blood 
clearance than IgGs, thereby offering the best compromise of molecular stability, 
clearance rate and tumor accumulation. We expect that the serum half-life of the 
antiFAP-mGITRL fusion protein in vivo is longer than for the monomeric form of soluble 
mGITRL (Ji et al., 2004) but similar to that of Fc-mGITRL (Hu et al., 2008). AntiFAP-
mGITRL and Fc-mGITRL constructs both show dimeric assembly, thus being present 
in the natural format of mGITRL. We determined a KD value of 1.2 μM of antiFAP-
mGITRL to mGITR, similar to the reported range of 4 to 15 μM for mGITRL 
(Chattopadhyay et al., 2008) and to the 1.8 μM as determined for mGITRL-Fc. With 1.7 
μM, the antiCD33-mGITRL fusion protein displayed a KD similar to that of antiFAP-
mGITRL, thereby being in the expected range since we assumed that the mGITRL 
domain of this construct would also induce dimer formation and that the antiCD33 scFv 
domain would not impair the biochemical characteristics in a different way than antiFAP 
scFv. 
The apparent affinities of our constructs for murine FAP are in the low nanomolar range 
like the reported KDapp of antiFAP scFv of 8 nM to recombinant mFAP in sandwich 
ELISA and 1.5 nM on mFAP-transfected cells (Brocks et al., 2001). In our study, the 
overall slightly lower apparent affinities of 4.5 nM for dimeric antiFAP-mGITRL and 29-
35 nM for antiFAP and antiFAP-hGITRL can be due to experimental setup as well as 
differences in the production system (E. coli versus NS0). The dimerization of the 
antiFAP-mGITRL fusion protein correlates with a 6-fold better KDapp on murine FAP-
expressing cells compared to monomeric constructs antiFAP-hGITRL and antiFAP. 
This avidity effect of the dimer together with the expected increased serum half-life due 
to its molecular weight, should not only enhance accumulation of antiFAP-mGITRL in 
the tumor but also increase retention time and, therefore, might prolong T cell 
costimulation in the tumor. The high affinity of our fusion protein for FAP and the low 
affinity to the costimulatory target are optimal to allow accumulation of the construct in 
the tumor without being quenched by receptor molecules on the surface of circulating T 
cells in the blood. 
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AntiFAP-mGITRL, but not antiFAP-hGITRL or antiFAP, bound to GITR on murine 
splenocytes, these results being a prerequisite for further costimulatory effects on 
murine T cells. Unexpectedly, on transfected CMS5a cells, murine and human GITRL 
domains each bound to both murine and human GITR. However, in line with published 
data (Bossen et al., 2006; Chattopadhyay et al., 2008; Chattopadhyay et al., 2007; 
Zhou et al., 2008), our surface plasmon resonance experiments did not show any 
crossreactivity between the murine and human GITR/GITRL system. Thus, we 
presume that the high receptor density on the transfected cells led to apparent 
interspecies crossreactivity of the fusion proteins since ectodomains of murine and 
human GITRL have 55% sequence identity at protein level and display considerable 
overall structural similarity as monomers (Chattopadhyay et al., 2008) and the murine 
and human GITR ectodomain orthologs are 57% homologous (Gurney et al., 1999). 
Low affinity interaction of mGITRL with GITR is sufficient for costimulation of T cells 
(Hu et al., 2008; Kanamaru et al., 2004; Ronchetti et al., 2004; Tone et al., 2003), thus 
our fusion protein efficiently costimulated CD4+ and CD8+ effector T cells resulting in 
enhanced proliferation, augmented production of IFN-γ by CD4+ and CD8+ and 
secretion of IL-2 by CD4+ T cells. Furthermore, in the presence of FAP-expressing 
cells, antiFAP-mGITRL is presented on the surface of these cells, resulting in an 
increase in costimulatory activity compared to unbound fusion protein. Interaction of the 
cell surface bound antiFAP-mGITRL with GITR on the T cell results in aggregation and 
crosslinking of GITR which enhances GITR signaling (Ji et al., 2004) and thus explains 
the increased activity if FAP-expressing cells are present. Anti-GITR antibody 
(Kanamaru et al., 2004; Ronchetti et al., 2004) or soluble GITRL (Ji et al., 2004) 
treatment has been reported to not only stimulate proliferation of CD4+25- T cells but 
also to enhance anti-CD3-induced secretion of IL-2, IFN-γ, IL-4 and IL-10. Whereas 
costimulation by antiFAP-mGITRL only slightly enhanced proliferation of CD4+ T cells 
in our study, the therapeutically more important secretion of IFN-γ or IL-2 was 
enhanced even 3-fold through presentation of the construct by FAP-expressing cells 
compared to only TCR-stimulated cells. Triggering of GITR with antiFAP-mGITRL 
induced stronger proliferation of CD8+ T cells than CD4+ T cells, consistent with data 
from stimulation with Fc-mGITRL (Hu et al., 2008). The overall lower induction of 
proliferation of CD4+ and CD8+ T cells compared to other reports (Cho et al., 2009; Hu 
et al., 2008; Ji et al., 2004; Kanamaru et al., 2004; Liao et al., 2010; Stephens et al., 
2004) is due to the use of soluble anti-CD3 antibody in our assays instead of support-
bound antibody. Most importantly, we show that antiFAP-mGITRL markedly reduces 
Treg-mediated suppression of proliferation and function of CD8+ T cells. Most studies 
analyzing the influence of GITR activation in suppression assays use CD4+25- effector 
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T cells and the few that investigate suppression of CD8+ T cells only quantified 
proliferation and not cytokine production (Hu et al., 2008; Shimizu et al., 2002). GITR 
triggering has been shown to restore the secretion of IL-2 by CD4+ T cells in 
suppression assays (Ji et al., 2004; Valzasina et al., 2005) with one exception stating 
that Fc-mGITRL failed to restore IL-2 production but restored proliferation to some 
extent (Liao et al., 2010). We focused on the less well characterized suppression of 
CD8+ T cells. At ratio 1:1 of BALB/c Treg:CD8+ Teff, suppression could be lowered to 
35% at highest concentration of antiFAP-mGITRL presented by FAP-expressing cells. 
The suppression of T cell proliferation mediated by Treg cells is a powerful effect and 
the extent to which this effect can be abrogated greatly depends on the experimental 
setup in vitro (Hu et al., 2008; Ji et al., 2004; Liao et al., 2010; McHugh et al., 2002; 
Nishioka et al., 2008; Shimizu et al., 2002; Stephens et al., 2004). A 1:1 ratio of 
Treg:CD8+ Teff does not reflect the physiological setting since it is around 1:4 in the 
tumor of a BALB/c CT26 model (Cho et al., 2009). Proliferation of BALB/c CD8+ T cells 
could be restored completely at 1:3 ratio in the presence of construct-presenting cells. 
IFN-γ production of CD8+ T cells could be increased beyond the level of control 
proliferation, thereby not only cancelling the effect of Treg cells but also activating the T 
cells even further. Most importantly, we demonstrate that presentation of antiFAP-
mGITRL by FAP-expressing cells is 100-fold more effective in overcoming Treg-
mediated suppression than unbound fusion protein, presumably due to clustering and 
crosslinking of GITR molecules on the surface of the CD8+ T cells. 
Agonistic anti-GITR treatment by DTA-1 antibody eradicates Meth A tumors and 
induces a long-lasting protective immune response (Ko et al., 2005). However, this 
DTA-1-mediated antitumor response is accompanied by some degree of autoimmune 
reaction (Cohen et al., 2006; Ko et al., 2005; Shimizu et al., 2002). Systemic 
administration leads to higher autoantibody titers than local injection of DTA-1 directly 
into the tumor. Ectopic expression of mGITRL on CT26 tumor cells delays tumor 
growth and enhances infiltration of CD8+ in the tumor (Cho et al., 2009) thus showing 
that local immune modulation through targeted anti-GITR treatment could lead to tumor 
immunity without systemic activation. Presentation of our antiFAP-mGITRL fusion 
protein through FAP-positive cells, i.e. tumor cells or activated fibroblasts, is a 
particularly efficient method not only to provide a site-specific and long lasting stimulus 
but also to enhance signaling through crosslinking of receptors on the target cell. To 
test this model in vivo, we studied the efficacy of antiFAP-mGITRL fusion protein in two 
different syngeneic murine tumor models. 
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In the first mouse model we investigated the efficacy of antiFAP-mGITRL in the 
treatment of an epithelial cancer that has been reported to induce formation of FAP+ 
stroma. First, determination of an optimal treatment schedule for tumor therapy was 
required. Since dimeric antiFAP-mGITRL displays approximately the same molecular 
weight as a minibody, we assumed similar biodistribution patterns. Minibodies show 
rapid tumor uptake, i.e. within a few hours, and minimal residual blood activity is 
reached after 24 h (Borsi et al., 2002; Wu and Senter, 2005; Yazaki et al., 2001). We 
therefore hypothesized that the antiFAP-mGITRL level in the blood should have 
reached very low levels after 24 h. Thus we decided to administrate our fusion protein 
i.v. on a daily schedule on five consecutive days. With repeated injections we aimed at 
further increasing the concentration of antiFAP-mGITRL in the tumor. 
We injected the colon carcinoma cell line CT26 subcutaneously into BALB/c mice. This 
cell line shows intermediate growth rate with tumors reaching 1.5 cm in diameter after 1 
month. We aimed at accumulating antiFAP-mGITRL in the tumor microenvironment 
through binding to the FAP+ fibroblasts in the stroma (Loeffler et al., 2006; Santos et 
al., 2009). Tumor progression could not be retarded with antiFAP-mGITRL or 
antiCD33-mGITRL but administration of mGITRL-Fc delayed tumor growth and even 
led to tumor rejection in one animal. In line with our results for mGITRL-Fc, another Fc-
mGITRL fusion protein had previously been reported to delay tumor growth of CT26 
and RENCA tumors (Hu et al., 2008). Even though we injected low amounts of only 1 x 
105 cells for tumor induction, the growth rate of the tumors was too fast to induce 
significant stroma formation. Histological analysis of the CT26 tumors showed densely 
packed tumor cells and very little stroma and thus no FAP+ activated fibroblasts. 
Furthermore, mGITRL-Fc fusion protein might be more stable in vivo due to the 
disulfide bridge stabilizing the dimer. The dimeric form of antiFAP-mGITRL, however, 
may be disrupted under certain physiological conditions in vivo. The resulting 
monomers would have the characteristics of a smaller immunoprotein such as a 
diabody and be more easily eliminated leading to lower tumor uptake than the dimer, 
thus hampering an efficient antitumor effect. 
Furthermore, we investigated the induction of a tumor-specific T cell response. In our 
study, the mGITRL-Fc treated mice developed AH-1 specific T cells in the blood. 
Strikingly, the mouse with the highest tumor-specific CD8+ T cell response was the one 
that rejected the tumor. Indeed, anti-GITR treatment has previously been reported to 
promote infiltration of T cells in the tumor (Cho et al., 2009; Ko et al., 2005) or induce 
and support tumor-specific T cells (Cohen et al., 2006; Nishikawa et al., 2008; 
Ramirez-Montagut et al., 2006), thereby suggesting a crucial role of CD8+ T cells in the 
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antitumor response. Moreover, depletion of CD8+ T cells abolishes the antitumor effect 
of anti-GITR treatment (Cho et al., 2009; Hu et al., 2008; Nishikawa et al., 2008; Piao 
et al., 2009; Ramirez-Montagut et al., 2006; Zhou et al., 2007). Therefore, either the 
direct effect of GITRL on CD8+ T cells or the indirect effect through inhibition of 
suppressive mechanisms is responsible for the enhanced survival of mGITRL-Fc 
treated mice.  
The second mouse model uses the highly aggressive osteosarcoma LM8 that develops 
tumors reaching 1.5 cm in diameter after 2 to 3 weeks. We showed that this cell line is 
FAP+ in culture, in contrast to its FAP- parental Dunn cell line. LM8 cells maintained 
their FAP expression in vivo, as confirmed by flow cytometry and IHC, thus being an 
adequate model for FAP-targeted immunotherapy of osteosarcomas. Furthermore, 
through the in vitro cell-based assays with splenocytes from C3H mice, we showed that 
antiFAP-mGITRL is able to costimulate T cells from that mouse strain. T cells from 
BALB/c and C3H mice showed the same trend of costimulatory effect in response to 
TCR and GITR activation but the magnitude of proliferation and cytokine production 
varied depending on the mouse strain. The antiFAP-mGITRL fusion protein enhanced 
IL-2 and IFN-γ production by C3H CD4+ T cells and increased proliferation and IFN-γ 
secretion by C3H CD8+ T cells. C3H CD8+ T cells showed approximately the same 
proliferation at 0.01 μg/ml anti-CD3 stimulus as BALB/c CD8+ T cells at a 100-fold 
higher dose of anti-CD3 (1 μg/ml). This difference is due to the fact that T cells from 
mice of different background have different activation thresholds. At ratio 1:1 of C3H 
Treg:CD8+, suppression of proliferation could be completely restored through 
membrane-bound antiFAP-mGITRL even at very low fusion protein concentrations. As 
in the suppression assays with BALB/c splenocytes, membrane-bound antiFAP-
mGITRL was 100-fold more effective in abolishing Treg-mediated suppression than 
unbound antiFAP-mGITRL. However, in the BALB/c costimulation assays, proliferation 
of CD8+ T cells could never be completely restored (at ratio 1:1 of Treg: CD8+). This is 
either due to the different sensitivity of the mouse strains to the anti-GITR costimulus or 
to the additional stimulation of BALB/c splenocytes with anti-CD28 antibody, which 
might positively act on Treg cells besides costimulating CD8+ effector T cells. 
Restoration of IFN-γ production by C3H CD8+ T cells was very weak, probably due to 
the missing anti-CD28 costimulus compared to BALB/c assays. To translate these in 
vitro results in a preclinical model, we injected C3H mice with LM8 cells and treated 
them with our fusion proteins. To our knowledge, only one study investigated the effect 
of GITR stimulation in a C3H tumor model. mGITRL-transfected squamous cell 
carcinoma cells (SCCVII) injected s.c. completely regressed after transient growth 
(Piao et al., 2009), thereby showing an antitumoral effect of GITR activation in C3H 
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mice. In our experiments, therapy of LM8 tumors with antiCD33-mGITRL did not delay 
tumor growth, whereas administration of antiFAP-mGITRL led to enhanced survival. 
Since neither the untargeted group treated with antiCD33-mGITRL nor the control 
group without GITRL (antiFAP treatment) showed a beneficial effect, we conclude that 
the antitumoral effect of antiFAP-mGITRL effect is due to the specific accumulation of 
the construct in the FAP+ tumor and to thereby mediated local GITR activation. To 
further enhance the antitumoral efficacy of antiFAP-mGITRL, the treatment schedule 
could be optimized or antiFAP-mGITRL may be used in combination with other 
molecules. 
Since antiFAP-mGITRL costimulated murine T cells and induced an antitumor 
response in a murine cancer model, the effects of GITR triggering in the human system 
are of great interest. For potential use of a GITRL fusion protein for human therapy, we 
cloned the antiFAP-hGITRL fusion protein. It displayed an affinity of 14 nM to hGITR in 
surface plasmon resonance experiments, which was in the range of the human 
GITR/GITRL system (Chattopadhyay et al., 2007). This 100-fold better affinity of the 
human system in comparison to the murine system is due to the different 
multimerization properties of hGITRL compared to mGITRL, together with the 
suspected formation of superclusters consisting of several hGITRL molecules (Zhou et 
al., 2008). These observations point to possible physiological differences between the 
murine and human GITR/GITRL system. The role of human GITR and its ligand is less 
well characterized than of the murine system and research results remain inconclusive. 
GITR is highly expressed on human NK cells but the effects of its triggering through 
GITRL are still controversial (Baessler et al., 2009; Baltz et al., 2007; Hanabuchi et al., 
2006). hGITRL costimulates human CD4+ and CD8+ T cells leading to proliferation and 
cytokine production (Levings et al., 2002; Tuyaerts et al., 2007). Although no inhibition 
of Treg-mediated suppression by GITRL treatment has been reported in human in vitro 
coculture assays so far (Levings et al., 2002; Tuyaerts et al., 2007), the overexpression 
of hGITRL on human monocyte-derived DCs enhances their capacity to prime tumor 
antigen-specific CD8+ T cells (Tuyaerts et al., 2007) and may therefore enhance a 
tumor-specific CD8+ T cell response. The outcome of a potential anti-GITR treatment in 
humans remains unclear and the interplay between tumor cells, T cells, NK cells and 
DCs in the setting of human GITR stimulation need to be further elucidated. Although 
some effects of GITR signaling might differ in human and mice, human T cells can be 
costimulated by activation of GITR, thereby representing a potential target for 
therapeutic interventions. A promising approach in human antitumor therapy would be 
to combine anti-GITR treatment with further approaches such as vaccines or mAb 
against other targets. CTLA-blockade, e.g., showed synergistic activity when combined 
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with anti-GITR treatment, leading to very potent antitumor effects in mice (Ko et al., 
2005; Mitsui et al., 2010). Therefore a combination therapy may generate effective 
tumor immunity in a clinical setting.  
Overall, tumor-specific GITR ligation through antiFAP-mGITRL has the potential to 
control tumor growth due to its unique characteristics of dimeric assembly, high affinity 
binding to mFAP and low affinity binding to mGITRL and its costimulatory properties. 
Therefore, at a low dose of fusion protein localizing to the tumor, crosslinking of GITR 
molecules by antiFAP-mGITRL can induce an antitumor effect in FAP+ sarcomas. Anti-
GITR therapy could be supported by vaccination, activation of APCs or other 
costimulatory signals in order to further enhance tumor immunity.  
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5.1 Amino acid sequence of antiFAP-hGITRL 
M G Q V Q L K Q S G A E L V K P G A S V K L S C K T S G Y T F T 
E N I I H W V K Q R S G Q G L E W I G W F H P G S G S I K Y N E 
K F K D K A T L T A D K S S S T V Y M E L S R L T S E D S A V Y 
F C A R H G G T G R G A M D Y W G Q G T S V T V S S A K T T P P 
K L E E G E F S E A R V D I L M T Q S P A S S V V S L G Q R A T 
I S C R A S K S V S T S A Y S Y M H W Y Q Q K P G Q P P K L L I 
Y L A S N L E S G V P P R F S G S G S G T D F T L N I H P V E E 
E D A A T Y Y C Q H S R E L P Y T F G G G T K L E I K R A G S G 
G G G S M G L Q L E T A K E P C M A K F G P L P S K W Q M A S S 
E P P C V N K V S D W K L E I L Q N G L Y L I Y G Q V A P N A N 
Y N D V A P F E V R L Y K N K D M I Q T L T N K S K I Q N V G G 
T Y E L H V G D T I D L I F N S E H Q V L K N N T Y W G I I L L 
A N P Q F I S G S E Q K L I S E E D L N S H H H H H H 
5.2 Amino acid sequence of antiCD33-mGITRL 
M K V Q L Q Q S G P E L V K P G A S V K I S C K A S G Y T F T D 
Y N M H W V K Q S H G K S L E W I G Y I Y P Y N G G T G Y N Q K 
F K S K A T L T V D N S S S T A Y M E L R S L T S E D S A V Y Y 
C A R G R P A M D Y W G Q G T S V T V S S A K T T P K L E E G E 
F S E A R V D I V L T Q S P A S L A V S L G Q R A T I S C R A S 
E S V D N Y G I S F M N W F Q Q K P G Q P P K L L I Y A A S N Q 
R S G V P A R F S G S G S G T D F S L N I H P M E E D D T A M Y 
F C Q Q S K E V P W T F G G G T K L E I K R A D T A P T G S G G 
G G S M G P W S L K P T A I E S C M V K F E L S S S K W H M T S 
P K P H C V N T T S D G K L K I L Q S G T Y L I Y G Q V I P V D 
K K Y I K D N A P F V V Q I Y K K N D V L Q T L M N D F Q I L P 
I G G V Y E L H A G D N I Y L K F N S K D H I Q K N N T Y W G I 
I L M P D L P F I S G S E Q K L I S E E D L N S H H H H H H 
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5.3 Amino acid sequence of antiFAP-mGITRL 
M G Q V Q L K Q S G A E L V K P G A S V K L S C K T S G Y T F T 
E N I I H W V K Q R S G Q G L E W I G W F H P G S G S I K Y N E 
K F K D K A T L T A D K S S S T V Y M E L S R L T S E D S A V Y 
F C A R H G G T G R G A M D Y W G Q G T S V T V S S A K T T P P 
K L E E G E F S E A R V D I L M T Q S P A S S V V S L G Q R A T 
I S C R A S K S V S T S A Y S Y M H W Y Q Q K P G Q P P K L L I 
Y L A S N L E S G V P P R F S G S G S G T D F T L N I H P V E E 
E D A A T Y Y C Q H S R E L P Y T F G G G T K L E I K R A G S G 
G G G S M G P W S L K P T A I E S C M V K F E L S S S K W H M T 
S P K P H C V N T T S D G K L K I L Q S G T Y L I Y G Q V I P V 
D K K Y I K D N A P F V V Q I Y K K N D V L Q T L M N D F Q I L 
P I G G V Y E L H A G D N I Y L K F N S K D H I Q K N N T Y W G 
I I L M P D L P F I S G S E Q K L I S E E D L N S H H H H H H 
5.4 Amino acid sequence of antiFAP 
M G Q V Q L K Q S G A E L V K P G A S V K L S C K T S G Y T F T 
E N I I H W V K Q R S G Q G L E W I G W F H P G S G S I K Y N E 
K F K D K A T L T A D K S S S T V Y M E L S R L T S E D S A V Y 
F C A R H G G T G R G A M D Y W G Q G T S V T V S S A K T T P P 
K L E E G E F S E A R V D I L M T Q S P A S S V V S L G Q R A T 
I S C R A S K S V S T S A Y S Y M H W Y Q Q K P G Q P P K L L I 
Y L A S N L E S G V P P R F S G S G S G T D F T L N I H P V E E 
E D A A T Y Y C Q H S R E L P Y T F G G G T K L E I K R A G S E 
Q K L I S E E D L N S H H H H H H 
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